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Summary 
 
Postoperative ileus or paralysis of the bowel is a transient but life-threatening impairment of 
bowel motility that occurs after surgery. Several pathogenic mechanisms responsible for 
postoperative dysmotility have been proposed including the involvement of autonomic 
nervous system, inhibitory humoral agents, anesthetic agents and local factors such as 
inflammation. Studies on inflammation progressively revealed a key role of sphingolipids in 
inflammatory responses. We have, therefore, investigated the involvement of sphingolipids in 
postoperative inflammation using a standardized surgical rodent model of intestinal 
manipulation. 
Our data demonstrate for the first time a direct correlation between the bioactive 
sphingolipids, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P), and 
postoperative intestinal inflammation. Sphingolipid analysis by mass spectrometry of both 
intestinal muscularis and mucosa after manipulation revealed a time dependent increase of 
S1P and C1P only in the muscularis layer when compared to control animals. We therefore 
examined the potential role of these two bioactive sphingolipids in postoperative 
inflammation using primary cultured rat intestinal smooth muscle (RISM) cells. Our studies 
indicate that S1P induces an appreciable proinflammatory response in these cells by elevating 
the cyclooxygenase-2 (COX-2) protein expression and formation of prostaglandin E2 (PGE2), 
the most abundant COX-2 product. S1P-induced COX-2 expression was strongly inhibited by 
pertussis-toxin (PTX), indicating the involvement of Gi/o protein coupled S1P receptors. 
Studies with pharmacological inhibitors indicate that S1P-induced COX-2 expression is 
mediated by both, extracellular-signal regulated kinase (ERK) and p38 mitogenic-activated 
protein kinase (p38 MAPK). In addition, an increased secretion of interleukin-6 (IL-6), after 
S1P administration was observed. We have also shown that S1P is involved in tumor necrosis 
factor-α (TNF-α) induced IL-6 secretion. Indeed, an increased sphingosine kinase (SK) 
activity was observed upon stimulation of RISM cells with TNF-α. C1P also enhanced PGE2 
synthesis but without any effect on COX-2 expression. However, C1P stimulated arachidonic 
acid release, which is indicative for the activation of phospholipase A2 (PLA2). Moreover, a 
direct correlation between mechanical stress and activation of S1P and C1P formation was 
established in RISM cells. Collectively, our results demonstrate that intestinal smooth muscle 
cells represent a major target for both, C1P and S1P activity. Thus, the elevated content of the 
two bioactive sphingolipids in this tissue could at least in part explain postoperative intestinal 
dysmotility. 
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In addition, in the present study the role of sphingolipids in lipopolysaccharide (LPS)-induced 
inflammatory reactions was addressed using a well-established sepsis model. We found an 
increase in the content of S1P and C1P after LPS administration indicating for the first time a 
direct involvement of these two bioactive sphingolipids in LPS signalling in an animal model. 
Moreover, studies on RISM cells reveal that SK mediates LPS-induced IL-6 secretion with a 
possible activation of ceramide kinase (CK).  
The findings that the two bioactive sphingolipids specifically increase in the muscle layer 
after intestinal manipulation and upon LPS administration, as well as the fact that they induce 
and mediate pro-inflammatory responses in RISM cells, make them interesting targets for 
development of novel anti-inflammatory drugs. Our data raise the possibility to overcome 
postoperative- or sepsis-induced ileus by a targeted disruption of the sphingolipid-mediated 
inflammatory pathway.   
  INTRODUCTION 
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1. Introduction 
1.1. The intestine  
 
The intestine, named  the inner tube of life in a special issue of the Science magazine, is a 
huge tube, in human adult about 10 meter-long, and homes about 10 times more 
microorganisms than human cells [Simpson et al., 2005]. Scientists consider the gut as the 
second brain due to the presence of enteric nervous system, embedded into the wall of the 
intestine. The intestine is divided into two major sections: small intestine and large intestine.  
1.1.1.  Anatomy and function of the small intestine 
 
The small intestine is a convoluted tube, extending from the pylorus to the large intestine. It is 
contained in the central and lower part of the abdominal cavity and is surrounded above and at 
the sides by the large intestine. It is connected to the vertebral column by a fold of 
peritoneum, the mesentery. The small intestine is divided into three structural parts: 
duodenum, jejunum and ileum. Food from the stomach is allowed into the duodenum by a 
muscle called pylorus or pyloric sphincter and is then pushed through the small intestine by a 
process of muscular contraction called peristalsis. The wall of the small intestine is composed 
of four layers: tunica serosa, tunica muscularis, tela submucosa and tunica mucosa (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Anatomy of the small intestinal wall.  
http://fire.biol.wwu.edu/lapsansk/348/DigestiveF05.ppt 
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Tunica muscularis consists of two layers: an external longitudinal, and an internal, circular 
layer responsible for the peristaltic movements of the whole intestine. Numerous cellular 
populations inhabit the intestinal muscularis such as smooth muscle, enteric neurons, 
endothelium, macrophages etc. Tela submucosa connects together the mucosa and muscularis 
layers. It consists of connective tissue containing blood vessels, lymphatic vessels and nerves 
and it is the strongest layer of the intestine. There is a band of smooth muscles so called 
muscularis mucosa separating mucosa from submucosa. Tunica mucosa is highly modified 
and organized into circular folds (plica circulares) that contain a core of submucosa. Several 
histologically distinct cell types exist in the epithelial layer of mucosa, among which the 
enterocytes are the main type. The epithelium, which is lining the mucosa, forms villi, finger-
like projections, each of which is surrounded by several very narrow pits, referred to as crypts 
(Fig.1).  Within each villus, there is a layer of loose connective tissue called lamina propria, 
which contains blood and lymphatic capillaries, nerves, lymphatic nodules and aggregated 
nodules (Peyers patches) and intestinal glands. 
The main physiological functions of the small intestine are digestion and absorption processes 
[Schiller and Feldman, 1997]. The duodenum is largely responsible for digestion of food 
macromolecules into their low components with the assistance of pancreatic enzymes and bile 
salts, whereas jejunum and ileum are mainly responsible for absorption of nutrients from the 
lumen into the blood stream. 
1.1.2. Postoperative ileus 
 
The functions of the intestine can be altered by many internal or external factors. For 
example, surgical procedures in the abdomen inhibit bowel motility, leading to a condition 
known as postoperative ileus.  
The term, ileus comes from the Greek word eilo that means to roll up tight. Postoperative 
ileus is a transient impairment of bowel motility that occurs after surgery and is usually 
considered an inevitable response to surgery. It is a significant clinical problem after surgical 
trauma and constitutes the most common reason for delayed discharge from the hospital after 
abdominal surgery. The prolonged dysfunction of bowel motility lasts for days with 
accumulation of secretions and gas, abdominal distension, nausea, vomiting, discomfort, pain 
and respiratory abnormalities including aspiration of gastrointestinal fluids. The economic 
impact of ileus has been estimated at 1 billion dollars per year in the Unites States [Livingston 
and Passaro, 1990]. Multiple causes of postoperative ileus have been suggested including the 
involvement of sympathetic reflexes, inhibitory humoral agents, anaesthetic agents and also 
  INTRODUCTION 
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inflammatory events [Luckey et al., 2003]. The hypothesis that postsurgical ileus is 
accompanied by a scenario of inflammatory events is supported by studies using a simple 
rodent model of intestinal manipulation. It was shown that the simple abdominal surgery leads 
to activation of resident muscularis macrophages and a subsequent upregulation of cytokines, 
chemokines and kinetically active substances (nitric oxide, prostaglandins) [Kalff et al., 1998; 
Kalff et al., 2003]. This local inflammatory milieu then participates in the recruitment of 
leukocytes into the muscularis with a significant decrease in muscle contractile activity [Kalff 
et al., 1999a; Kalff et al., 1999b].  
Although postoperative dysmotility has been documented by numerous investigators [Baker 
and Webster, 1968; Dahlgren and Selking, 1972; Graber et al., 1982; Condon et al., 1986; 
Schippers et al., 1991], the exact underlying mechanisms of this important clinical problem 
are still ill defined. To date, no accepted pharmacological prevention or treatment of 
postoperative ileus exists. Therefore, the elucidation of pathological events at the molecular 
and cellular level could help in finding new therapeutic strategies for prevention and/or 
treatment of this surgical complication. 
1.1.3. Sepsis-induced ileus 
 
The intestinal muscle dysfunction also occurs during sepsis. Sepsis (in Greek Σήψις, 
putrefaction) is a systemic inflammatory response to severe bacterial infection. It is a leading 
cause of morbidity and mortality in severely ill patients with about 9.3% of total deaths in the 
United States [Angus et al., 2001]. Sepsis frequently occurs after abdominal surgery, 
hemorrhagic shock, burns or trauma due to intestinal barrier failure and bacteria or endotoxin 
(lipopolysaccharide) translocation [Pape et al., 1994; Saadia, 1995; Deitch et al., 1996; 
Lichtman, 2001]. 
Lipopolysaccharide (LPS) often called endotoxin is an important structural component of the 
outer leaflet of the outer membrane of gram-negative bacteria such as Escherichia coli, 
Salmonella, Pseudomonas and others [Beutler and Rietschel, 2003] (Fig. 2). This glycolipid is 
the main constituent that is recognized by the innate immune system, the first line of defence 
against infection. Chemical analyses showed that LPS consists of a hydrophobic domain (lipid 
A), the toxic component of LPS that anchors the molecule in the outer membrane and a 
polysaccharide side chain, the non-toxic but immunogenic portion of LPS. 
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Fig. 2 A gram-negative bacterium. Elecron micrograph of Escherichia coli with a schematic representation of 
LPS in the bacterial cell wall [Beutler and Rietschel, 2003].  
 
During gram-negative infection, LPS interacts through its lipid A, with Toll-like receptor 4 
(TLR4) (a homologue of Drosophila receptor Toll) present on the cell surface of monocytes, 
macrophages and non-hematopoietic cells [Akira and Takeda, 2004; Hirata et al., 2005; Singh 
and Schwartz, 2005; Rumio et al., 2006]. As a consequence, LPS activates several 
intracellular signalling pathways resulting in the activation of different transcription factors 
(NF-kB, AP-1 Fos, Jun). Subsequently, these initiate the transcription of many genes 
necessary for the effector functions of innate immunity such as cytokines and adhesion 
molecules [Ulevitch, 1999; Alexander and Rietschel, 2001]. These physiological changes 
usually constitute a beneficial response for the affected host. However, in the case of bacterial 
sepsis an overwhelming production of proinflammatory cytokines such as TNF-α, IL-1 
occurs. The overproduction of cytokines causes abnormal body temperature and respiratory 
rate, a drop in blood pressure and other devastating pathophysiological effects that ultimately 
lead to hemodynamic shock and multiple organ failure [Dinarello and Bunn, 1997; Calandra, 
2001]. 
The intestine is not only the primary source of bacteria and bacterial toxins but is also a major 
target of bacterial-induced organ dysfunction. It is known that LPS from gram-negative 
bacteria is a causative factor of sepsis-induced ileus [Cullen et al., 1999a; Lodato et al., 1999]. 
It has been shown that the induction of sepsis by administration of living bacteria or 
endotoxin initiates an inflammatory cascade within the intestinal smooth muscle layer and a 
subsequent decrease in smooth muscle contractility [Eskandari et al., 1997].  
As with postoperative ileus, there is no accepted pharmacological prevention or treatment of 
sepsis-induced ileus. Therefore, insights gained by studying sepsis-induced muscularis 
inflammatory events maybe helpful to develop an effective treatment strategy. 
 
 
 Lipopolysaccaride
Outer membrane
Peptidoglycan
Inner membrane
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1.2. Inflammation 
 
Inflammation is a defensive response that begins after cellular injury, which may be caused by 
microbes, physical agents (burns, radiation, trauma), chemicals (toxins, caustic substances), 
necrotic tissue and/or immunological reaction. As an indicator of disease, inflammation has 
been recognized for centuries. Almost 2000 years ago, the Roman physician, Celsus, 
described the four cardinal signs (symptoms) of inflammation: rubor et tumor cum calore et 
delore (redness and swelling with heat and pain). Later on, another highlight pioneer in the 
history of inflammation research, Virchow, described the fifth cardinal sign of inflammation, 
function laesa (loss of function). The acute inflammatory response is characterized by a series 
of events including an increase in blood flow and vascular permeability and the accumulation 
of various inflammatory cells (neutrophils, monocytes, dendritic cells, mast cells and 
lymphocytes) at the site of tissue trauma. These phagocytic cells ingest foreign material and 
cell debris. Finally, the injurious stimulus is cleaned and normal tissue structure and function 
is restored. However, if an acute response is not resolved it becomes chronic. Prolonged 
inflammation is a hallmark of many chronic diseases and autoimmunity. Several types of 
mediators released or synthesized after target cell activation are known to play a role in the 
inflammatory response such as vasoactive amines (histamine, bradikinin), leukotrienes, 
prostaglandins and various cytokines and chemokines. Recent studies have demonstrated the 
activity of various sphingolipid molecules as potent mediators of the inflammatory pathway.  
Inflammatory responses in the bowel wall contribute, at least in part to postoperative ileus. 
Although the inflammatory mediators participating in postoperative ileus have not been well 
defined, production of prostaglandins and induction of IL-6 seem to be an important cause of 
postoperative ileus in rats [Schwarz et al., 2001; Wehner et al., 2005] 
1.2.1. Prostaglandin generation: phospholipase A2 enzymes and 
cyclooxygenases 
 
Prostaglandins belong to a class of lipid mediators known as eicosanoids (from the Greek 
eicosa=twenty; for twenty carbon fatty acid derivatives) that are involved in various 
homeostatic biological functions and inflammation [Funk, 2001]. Prostaglandins are produced 
by most cells in our body and act as autocrine or paracrine lipid mediators. They are 
synthesized from membrane-released arachidonic acid when cells are activated by mechanical 
trauma, cytokines, growth factors, LPS or other stimuli [Scholz, 2003]. Prostaglandin 
biosynthesis is regulated by three enzymatic reactions. First, arachidonic acid, which is stored 
at the sn-2 position of the membrane glycerophospholipids, is released by the hydrolytic 
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action of phospholipase A2 (PLA2) of which several isoenzymes are known. Further on, 
arachidonic acid is metabolized to prostaglandin H2 (PGH2) by cyclooxygenase (COX) (1 and 
2) enzymes also known as prostaglandin H synthases (PGHS).  COX enzymes catalyze both: 
i) the bis-oxygenation of arachidonic acid leading to production of PGG2 (COX reaction) and 
ii) reduction of 15-hydroperoxide of PGG2 leading to formation of PGH2 (peroxidase 
reaction). PGH2 is subsequently converted to the most important biologically active end 
products such as PGD2, PGE2, PGF2α, PGI2 (prostacyclin) or TXA2 (tromboxane) by specific 
cellular synthases (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Prostanoid biosynthetic pathway. In response to extracellular stimuli such as a cytokine, a growth factor 
or a circulating hormone, phospholipases are activated and arachidonic acid is hydrolyzed from the sn-2 position 
of membrane phospholipids. Arachidonate is converted by PGHS to PGH2, and then PGH2 is isomerised to 
biological active prostanoid products [Smith et al., 1996]. 
 
Once formed, the prostaglandins are released from the cells through a known prostaglandin 
transporter (PGT) [Schuster, 1998] and act via specific cell surface G-protein coupled 
receptors (EP1-4, DP1-2, FP, IP, TPα-β), thus exerting their biological function [Hirai et al., 
2001; Narumiya and FitzGerald, 2001; Simmons et al., 2004]. Of these, PGE2 is the most 
common prostanoid, being produced by a wide variety of cells and tissues and playing crucial 
roles in various biological events. Moreover, PGE2 is generated in substantial amounts at the 
site of inflammation and can mediate many of the pathological features of inflammation, 
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including vasodilation, febrile responses and platelet aggregation [Williams and Peck, 1977; 
Dinarello, 1984; Ballou et al., 1992]. The regulation of the prostaglandin biosynthetic 
pathway has become more complex with the discovery of multiple PLA2 and COX enzyme 
forms. 
1.2.1.1. Phospholipase A2 enzymes 
 
Phospholipase A2 (PLA2) enzymes hydrolyse the sn-2 ester bond of phospholipids to release 
free fatty acids and lysophospholipids. Depending on the Ca2+ requirement for their enzymatic 
activity, PLA2 can be classified in three categories: secretory PLA2 (sPLA2) that require 
millimolar concentrations of Ca2+, the cytosolic PLA2 (cPLA2) that require micromolar 
concentration of Ca2+ and the Ca2+-independent PLA2 (iPLA2) that do not require Ca2+ for 
activity [Akiba et al., 2004]. Of these, cPLA2 has been shown to play a pivotal role in 
biosynthesis of inflammatory lipid mediators (prostaglandins, leukotrienes) since it is highly 
selective for glycerophospholipids containing arachidonic acid in the sn-2 position [Shimizu 
and Wolfe, 1990; Clark et al., 1995; Hirabayashi et al., 2004]. While α-, β-, γ-isoforms of 
cPLA2 exist, cPLA2α appears to be most relevant for prostaglandin formation during acute 
and chronic inflammation. cPLA2α is comprised of two catalytic domains A and B and a C2 
domain also known as calcium-lipid binding domain or CaLB domain. cPLA2α does not 
require calcium for catalysis but for binding to the membrane, this association being stabilized 
by prolonged calcium elevation that causes an abundant arachidonic acid release. cPLA2α can 
be activated by mechanical trauma, cytokines, LPS, hormones and antigens. This triggers 
translocation of PLA2α to endoplasmatic reticulum (ER), Golgi apparatus and nuclear 
membranes where it induces together with COX enzymes PGE2 formation. Studies with 
cPLA2α-deficient mice have implicated this enzyme in many pathological conditions, 
especially those which are associated with inflammation [Bonventre et al., 1997; Nagase et 
al., 2000; Takaku et al., 2000; Miyaura et al., 2003; Kalyvas and David, 2004]. 
1.2.1.2. Cyclooxygenases 
 
In 1990 it was established that COX, the enzyme that catalyses the conversion of arachidonic 
acid to prostaglandins, exists in two isoforms, commonly referred to as COX-1 and COX-2 
[Xie et al., 1991; Vane et al., 1994]. They are membrane-bound proteins, COX-1 residing 
primarily in the ER, whereas COX-2 is located predominantly in the perinuclear envelope. 
Recent studies suggested the existence of another COX enzyme, namely COX-3, a splicing 
variant of COX-1, which is known to be a 5.2-kb transcript most abundant in the cerebral 
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cortex and heart [Chandrasekharan et al., 2002]. COX-1 is expressed constitutively in most 
tissues and cell types. Therefore, COX-1 is considered to exert housekeeping functions such 
as maintenance of vascular tone and mucosal integrity in the gastrointestinal tract [Adami et 
al., 2006]. Unlike COX-1, COX-2 is the inducible isoform whose expression is highly up-
regulated in many cell types in response to trauma, proinflammatory agents such as IL-1, 
TNF, LPS as well as by growth factors [Raz et al., 1989; Ferraz et al., 1997]. Thus, COX-2 is 
mainly considered to mediate inflammation. COX-2 has emerged as the isoform responsible 
for the synthesis of eicosanoids in pathological processes such as acute and chronic 
inflammation, neurodegenerative diseases including amyotrophic lateral sclerosis and 
Alzheimer`s disease as well as in heart diseases [Turini and DuBois, 2002]. In addition, COX-
2 is also found to be overexpressed in transformed cells and in malignant tissue [Eberhart et 
al., 1994; Kargman et al., 1995; Ristimaki et al., 1997]. Importantly, COX-2 null mice were 
protected against the development of both intestinal and skin tumors [Oshima et al., 1996; 
Morham et al., 1997]. Both isoforms are inhibited by glucocorticoids and non-steroid anti-
inflammatory drugs (NSAIDs) like aspirin [Hinz and Brune, 2002]. However, NSAIDs 
administration is accompanied by many side effects including gastrointestinal ulceration, 
bleeding, and platelet dysfunctions due to suppression of COX-1 derived-prostaglandins, 
which are required for normal homeostatic processes. Therefore, during the last years much 
research has been done to develop potent and selective COX-2 inhibitors able to limit 
inflammation without adverse effects [Kawamori et al., 1998; Brune and Hinz, 2004].  
1.2.2. Cytokine signalling: tumor necrosis factor-α and the interleukins 
 
Cytokines represent another important class of mediators involved in induction of the 
inflammatory response and in immunity [Sartor, 1994; Borish and Steinke, 2003]. They are 
low molecular weight proteins or glycoproteins secreted by most cells of the immune system 
as well as by other cells in the body in response to a number of inducing stimuli. The cytokine 
family includes: interleukins (IL), interferons (IFN), tumor necrosis factors (TNF), 
transforming growth factor β (TGF-β), and chemokines. Although most cytokines exert pro-
inflammatory effects through binding to specific cytokine receptors present on their target 
cells, some of these cytokines elicit anti-inflammatory functions such as, IL-1ra, IL-10, IL-13, 
TGF-β [Del Prete et al., 1993; Muchamuel et al., 1997; Arend and Guthridge, 2000; Wahl and 
Chen, 2005]. Therefore, it is important to study the levels and the action of these molecules in 
order to understand the mechanisms of inflammatory states. Among many cytokines 
described so far, three in particular, namely, TNF-α, IL-1β and IL-6 attracted significant 
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attention due to their role in the pathophysiology of many inflammatory responses as well as 
of septic shock [Fiocchi, 1998; Monack et al., 2004]. 
1.2.2.1. Tumor necrosis factor-α 
 
TNF-α previously termed cachectin because of its possible role in cachexia or wasting effect 
[Beutler, 1989], belongs to the TNF family that includes 19 ligands [Aggarwal, 2003]. It is 
mainly produced by monocytes and macrophages but can be released also by other cells 
including, neutrophils, mast cells, lymphocytes and endothelial cells. TNF-α is produced in 
response to many extracellular stimuli such as cytokines, heat shock, UV irradiation and 
microbial infection. It is considered to be a primary mediator of immune regulation, sepsis 
shock and inflammatory response as well as an anti-tumor factor [Tracey and Cerami, 1993]. 
TNF-α has potent proinflammatory effects since it activates neutrophils, stimulates 
endothelial cells to produce adhesion molecules and increases vascular permeability 
facilitating migration of inflammatory cells to the sites of inflammation [Oppenheim, 2001; 
Borish and Steinke, 2003]. TNFs exert their effects by binding to specific cell surface 
receptors. There are two types of TNF receptors: TNFR1 expressed in almost all cell types 
and TNFR2 which seems to be highly regulated and expressed in immune and endothelial 
cells [Tartaglia and Goeddel, 1992]. TNFRs signal via distinct motifs in their 
intracytoplasmatic domains such as TNFR-associated factor (TRAF) and TNF-R-associated 
death domain protein (TRADD) [Arch et al., 1998]. These motifs associate with different 
adaptors and thus signal distinct cell functions [Clark et al., 2005]. TNFR1 appears to be 
primarily responsible for the proinflammatory effect of TNF-α under physiological 
conditions. For instance, TNFR1 can activate NF-kB by recruiting TRADD, TRAF2 and 
receptor interacting protein (RIP) [Chen and Goeddel, 2002]. NF-kB is a transcription factor 
that regulates the synthesis of many proteins that function in inflammatory pathways 
including, IL-1, IFN-ß, TNF-α and cyclooxygenases [Ghosh et al., 1998]. 
1.2.2.2. Interleukin-1ß 
 
IL-1ß, a member of IL-1 family is a key mediator of pro-inflammatory responses.  It was 
originally described as the endogenous pyrogen because it has pronounced fever-induced 
properties in rabbits [Huising et al., 2004]. IL-1ß is synthesized as a large precursor protein by 
many cell types including monocytes and lymphocytes. Pro-IL-1ß is biologically inactive and 
requires cleavage by caspase-1 to produce an active 17 kDa protein, which is secreted. IL-1ß 
exerts biological effects by binding to specific cell surface receptors [Subramaniam et al., 
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2004]. It activates T-lymphocytes, B-cell proliferation and immunoglobulin production, 
stimulates synthesis of acute phase proteins and endothelial cell adherence of leukocytes 
through up-regulation of adherence molecules (ICAM-1, VCAM-1, E-selectin) [Oppenheim, 
2001]. 
1.2.2.3.  Interleukin-6 
 
Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biological activities 
[Papanicolaou et al., 1998]. Similar to TNF-α, IL-6 is produced not only by immune cells but 
also by many nonimmune cells such as osteoblasts, keratynocytes, intestinal epithelial cells 
and smooth muscle cells [Heinrich et al., 1990; Loppnow and Libby, 1990; McGee et al., 
1993]. It has potent proinflammatory effects including immunoglobulin production, T-cell 
activation and differentiation, induction of fever and synthesis of acute phase proteins such as 
C-reactive protein and complement components [Oppenheim, 2001]. A variety of molecules 
including IL-1, TNF-α, PDGF, IFN-β and calcium ionophore A23187 induce production of 
IL-6. On the other hand, IL-6 inhibits the secretion of IL-1 and TNF-α and induces the 
synthesis of IL-receptor antagonist (IL-Ra) and glucocorticoids, which are known for their 
anti-inflammatory actions suggesting that IL-6 has both, proinflammatory and anti-
inflammatory properties [Libert et al., 1994; Xing et al., 1998]. In models of chronic 
inflammation, IL-6 has a proinflammatory effect that favours the recruitment of mononuclear 
cells such as macrophages and lymphocytes at the site of injury [Alonzi et al., 1998; 
Yamamoto et al., 2000], whereas in models of acute inflammation IL-6 exhibits an anti-
inflammatory profile [Xing et al., 1998]. 
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1.2.3. Sphingolipids 
1.2.3.1. Sphingolipid metabolism and function. General remarks 
  
In 1884, the German pathologist, J.L. W. Thudichum discovered and named a class of new 
lipids while studying the chemical composition of the brain.  Hydrolysis of these lipids 
produced a compound, which Thudichum named  sphingosin due to its enigmatic Sphinx-
like properties [Thudichum, 1884]. Thus, this class of lipids became known as the 
sphingolipids because of their common sphingosine backbone. Sphingolipids are ubiquitous 
constituents of membranes in animals, plants, fungi, yeast and some prokaryotic organisms 
and they were originally regarded as structural and inert components of cell membranes. 
Currently, many studies support their roles in modulating various cellular events such as 
proliferation, differentiation, apoptosis and inflammation [Merrill et al., 1997; El Alwani et 
al., 2006]. Sphingolipid metabolism is a complex network of highly regulated pathways that 
produces bioactive molecules including primarily ceramide, ceramide-1-phosphate, 
sphingosine -1-phosphate, sphingosine and glucosylceramide (Fig. 4).  
Sphingolipid biosynthesis starts at the cytoplasmic leaflet of the ER with the condensation of 
palmitoyl-CoA and L-serine yielding 3-ketosphinganine. The reaction is catalysed by a 
pyridoxal phosphate (PLP)-dependent enzyme serine palmitoyltransferase and represents the 
rate-limiting step of sphingolipid biosynthesis [Mandon et al., 1992]. The next step is the 
reduction of 3-ketosphinganine to D-erythro-sphinganine in the presence of NADPH. 
Subsequently, sphinganine is acylated to dihydroceramide by (dihydro) ceramide synthase. 
This enzyme is inhibited by a fungal toxin, fumonisin B1 [Vesper et al., 1999]. Insertion of 
the 4,5-trans-double bond into the sphingoid base backbone of dihydroceramide results in the 
formation of ceramide [Rother et al., 1992; Michel et al., 1997] (Fig. 4). Ceramide is the 
central lipid in the metabolism of sphingolipids [van Echten-Deckert and Herget, 2006]. Once 
formed, it serves as a precursor for more complex glycosphingolipids and sphingomyelin 
(SM). SM is synthesized by the transfer of phosphorylcholine from phosphatidylcholine to 
ceramide, liberating diacyglycerol through the action of sphingomyelin synthase [Ramstedt 
and Slotte, 2002]. Neutral glycosphingolipids like glucosylceramide (GlcCer) and 
galactosylceramide (GalCer) are generated by a direct transfer of a single sugar from the 
appropriate sugar nucleotide (UDP-Glc, UDP-Gal, etc) to ceramide by glycosyltransferases 
[van Echten-Deckert and Dragusin, submitted] Another important metabolite that can be 
generated from ceramide is ceramide-1-phosphate (C1P), which is formed by the action of 
ceramide kinase [Bajjalieh et al., 1989] (Fig. 4).  
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Fig. 4 Scheme of sphingolipid metabolism. Ceramide is the central molecule in the metabolism of 
sphingolipids. It can be formed de novo (red arrows), from hydrolysis of sphingomyelin or glycosphingolipids, 
or from dephosphorylation of ceramide-1-phosphate (C1P) (black arrows) or recycling of sphingosine (salvage 
pathway). Ceramide can serve as a precursor in many biosynthetic pathways (green arrows). The major pathway 
for catabolism of ceramide is its deacylation by ceramidases to sphingosine, which in turn is phosphorylated to 
generate sphingosine-1-phosphate (S1P) (dark blue arrows). S1P can be irreversibly cleaved by lyase to 
phosphoetanolamine and hexadecenal (dark blue arrows) or it can be dephosphorylated by phosphatases that 
regenerate sphingosine in the ceramide salvage pathway (light blue arrows).  GSL, gycosphingolipids; PLP, 
pyridoxal phosphate; NADPH, nicotine adenine dinucleotide phosphate. [Wedeking and van Echten-Deckert, 
2006] 
 
Catabolism of sphingolipids occurs primarily in the lysosomal compartment through the 
action of several distinct hydrolases that sequentially remove the headgroups of complex 
sphingolipids, resulting in the formation of ceramide [Hannun et al., 2001]. Non-lysosomal 
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hydrolases also exist in other compartments including golgi apparatus and plasma membrane 
[Goni and Alonso, 2002]. SM and glycosphingolipids are degraded to ceramide through the 
action of sphingomyelinases (SMase) and exoglycosidases, respectively [Hannun, 1994; van 
Echten-Deckert and Herget, 2006]. The major pathway for catabolism of ceramide is its 
deacylation by ceramidases to sphingosine [Hassler and Bell, 1993]. In turn, sphingosine may 
be phosphorylated into sphingosine-1-phosphate (S1P) by the action of sphingosine kinase 
(SK), or acylated by ceramide synthase in the salvage pathway to form ceramide [Hannun et 
al., 2001] (Fig. 4). S1P can also enter the salvage pathway through the action of phosphatases 
that regenerate sphingosine, or it can be irreversibly cleaved to phosphoethanolamine and 
hexadecenal by a pyridoxal 5`-phosphate (PLP)-dependent lyase [Van Veldhoven, 2000; 
Ikeda et al., 2004] (Fig. 4). The aldehyde intermediate is oxidized to fatty acid whereas 
phosphoethanolamine can be utilized for the synthesis of phosphatidylethanolamine, both of 
which may enter glycerolipid pathway [Merrill and Sweeley, 1996].  
Experimental evidence over the last decades supports the notion that sphingolipids are 
involved in a wide variety of biological processes. Together with cholesterol they form 
distinct microdomains in the plasma membranes that may serve primarily for cellular signal 
transduction [Szabo et al., 2004]. Complex glycosphingolipids enriched in the plasma 
membrane mediate interaction with the extracellular matrix and serve as attachment sites for 
microorganisms, microbial toxins and viruses [Holmgren et al., 1975; Markwell et al., 1981; 
Merrill and Sweeley, 1996]. Instead sphingomyelin influences membrane rigidity and stability 
[Ridgway, 2000]. In addition to their structural and regulatory roles, sphingolipids have been 
implicated in diverse processes including regulation of transformation, differentiation, 
proliferation, apoptosis and inflammation [Ogretmen and Hannun, 2004; Wedeking and van 
Echten-Deckert, 2006]. Among many sphingolipids with important biological roles, ceramide, 
sphingosine-1-phosphate and recently ceramide-1-phosphate received significant attention. 
1.2.3.1.1. Ceramide 
 
Ceramide has proven to be a powerful signalling molecule produced in response to various 
stimuli such as cytokines, heat, chemotherapeutic agents, UV irradiation, LPS and other 
agents [Obeid et al., 1993; Chang et al., 1995; Haimovitz-Friedman et al., 1997; Hannun and 
Obeid, 2002]. Ceramide, once generated, is a mediator of multiple cellular signalling 
pathways that involve cell cycle arrest [Jayadev et al., 1995], cell differentiation [Okazaki et 
al., 1989], apoptosis [Obeid et al., 1993], aging, [Venable et al., 1995], and other cell 
responses. Ceramide actions are mediated by regulation of intracellular effectors such as 
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ceramide-activated protein-phosphatases (CAPP), namely PP1A and PP2A [Chalfant et al., 
1999] ceramide-activated protein kinase (CAPK) [Zhang et al., 1997], PKC ζ [Wang et al., 
2005] and cathepsin D [Heinrich et al., 1999]. Ceramide is the common intermediate for S1P 
and C1P.  
1.2.3.1.2. Sphingosine-1-phosphate 
 
Unlike ceramide, which has been associated with growth arrest and cell death, sphingosine-1-
phosphate (S1P) enhances growth and survival in diverse cell types [Spiegel and Milstien, 
2002]. S1P is generated from sphingosine through the action of two SKs: SK1 and SK2 
[Kohama et al., 1998; Liu et al., 2000a]. Although both SKs are closely related and 
phosphorylate sphingosine to produce S1P, they show different effects on cell survival and 
sphingolipid metabolism [Maceyka et al., 2005]. In contrast to other sphingolipid second 
messengers, S1P might have dual functions. First, S1P was found to act as an extracellular 
ligand by binding to a family of five specific G-protein coupled receptors (GPCR), originally 
named endothelial differentiation gene receptors (EDG-1,-3,-5,-6,-8) [Lee et al., 1998] and 
now termed S1P1-5 receptors [Spiegel and Milstien, 2003] (Fig. 5). These receptors are 
ubiquitously expressed and coupled to various heterotrimeric G proteins leading to activation 
of numerous downstream signalling pathways. Consequently, S1P has the ability to regulate 
various physiological processes including angiogenesis and vascular maturation [Wang et al., 
1999; Liu et al., 2000b], heart development [Kupperman et al., 2000] and immunity [Graeler 
et al., 2002; Mandala et al., 2002], depending on the tissue-specific expression of S1P 
receptors and the respective coupled G proteins.  
Later on, it has been suggested that S1P also functions as an intracellular second messenger 
generated in response to a variety of external stimuli in particularly growth and survival 
factors including platelet-derived growth factor (PDGF) [Olivera and Spiegel, 1993], 
epidermal growth factor, (TNF-α) [Xia et al., 2002], nerve growth factor [Edsall et al., 1997], 
S1P itself [Meyer zu Heringdorf et al., 2001] and others, which activate SK to generate S1P 
[Payne et al., 2002] (Fig. 5). Intracellular S1P has been found to play a key role in calcium 
mobilization, cell growth and survival [Olivera et al., 1999]. Extracellular and intracellular 
actions of S1P are mediated by activation of different MAPKs [Gonda et al., 1999; Shu et al., 
2002].  
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Fig. 5 Dual function of sphingosine-1-phosphate. S1P can act as a second messenger or as an extracelullar 
ligand. Cellular S1P is produced in response to diverse agonists such as, growth factors or cytokines that bind to 
cell surface receptors and activate sphingosine kinases (SKs). SKs phosphorylate sphingosine leading to 
increased generation of S1P.  S1P can also function as a specific ligand of G-protein-coupled S1P receptors. S1P 
receptors couple with various G proteins such that S1P can mediate distinct biological processes. 
1.2.3.1.3. Ceramide-1-phosphate 
 
Another bioactive phosphosphingolipid is ceramide-1-phosphate (C1P), which is produced in 
mammalian cells by phosphorylation of ceramide by ceramide kinase. C1P can also be 
generated from sphingomyelin by sphingomyelinase D (SMase D), the main component of the 
venom from Loxosceles reclusus (brown recluse spider) [Kurpiewski et al., 1981; Merchant et 
al., 1998]. However, a mammalian SMase D has not been described so far. Although C1P was 
identified more than a decade ago, its potential biological functions have only become clear in 
the last few years. The existence of C1P was first reported in human leukaemia (HL-60) cells 
[Dressler and Kolesnick, 1990]. The first data regarding C1P activity indicated that it 
stimulates DNA synthesis and promotes cell division in rat fibroblasts [Gomez-Munoz et al., 
1995]. Other important findings implicated C1P in phagocytosis by promoting 
phagolysosome formation [Hinkovska-Galcheva et al., 1998], in blocking apoptosis through 
inhibition of acidic SMase in macrophages [Gomez-Munoz et al., 2004] and in mast cell 
degranulation in a calcium-dependent manner [Mitsutake et al., 2004]. Unlike S1P, C1P does 
not act through a cell surface receptor. Recent studies suggest an intracellular role for C1P as 
second messenger that involves C1P in inflammatory responses [Pettus et al., 2004a]. 
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1.2.4. MAPKs in inflammatory responses 
 
Considerable attention has also been given to mitogen-activated protein kinases (MAPKs) as 
possible targets for development of novel anti-inflammatory therapeutics. Inhibitors targeting 
these pathways have been developed and preliminary data suggest that they indeed exhibit 
anti-inflammatory activity. 
 The MAPK cascade is one of the most ancient and evolutionarily conserved signalling 
pathways, which is also important for many physiological processes [Seger and Krebs, 1995]. 
MAPK pathways can be activated by a wide variety of different stimuli including hormones 
and growth factors, cytokine, environmental stresses such as osmotic shock, ionizing radiation 
and ischemic injury. In turn, MAPK signalling pathway coordinates activation of gene 
transcription, protein synthesis, cell cycle machinery, cell death and differentiation 
[Herskowitz, 1995; Marshall, 1995; Kyriakis and Avruch, 1996]. The first enzyme that is 
activated in MAPK cascade is a Ser/Thr kinase known as MAPK kinase kinase (MAPKKK).  
These MAPKKKs phosphorylate and activate MAPK kinases (MKK), which are dual-
specificity kinases catalysing the phosphorylation of Tyr or Ser/Thr residues in its target 
proteins.  Active MKK activates MAPK through phosphorylation of both, a Thr and a Tyr, 
which are separated in the protein by a single amino acid [Garrington and Johnson, 1999; 
Chang and Karin, 2001]. MAPKs are also Ser/Thr kinases that phosphorylate many different 
proteins including nuclear transcription factors and other protein kinases that mediate cellular 
processes (Fig. 6). MAPK-catalysed prosphorylation of substrate proteins can turn on or off 
the activity of the respective target. MAPKs are inactivated by MAPK phosphatases [Farooq 
and Zhou, 2004].  
There are three well-characterized subfamilies of MAPKs in mammalian cells. These MAPKs 
include the extracelullar signal-regulated kinases (ERK) [Schaeffer and Weber, 1999], the p38 
MAP kinases [Ono and Han, 2000], and the c-Jun NH2-teminal kinases (JNK) [Davis, 2000].  
ERK pathway was identified downstream of oncogene Ras and is involved in the regulation 
of cell growth and differentiation. There are two isoforms of ERK, ERK1 and 2, which are 
sometimes referred to as p44/42 MAPK. They are widely expressed and activated by many 
different stimuli, including growth factors, cytokines, virus infection, ligands for G-protein 
coupled receptors (GPCRs) [Ashwell, 2006]. 
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Fig. 6 MAP kinase pathways. Mitogen-activated protein kinases (MAPKs), which integrate and process various 
extracelullar signals. The MAPK cascade consists of a series of three protein kinases  a MAPK and two 
upstream components, MAPK kinase (MAPKK or MEK) and MAPKK kinase (MAPKKK). ERK, extracellular 
signal-regulated kinase; JNK, c-Jun N-terminal kinase [Kumar et al., 2003].  
There is relative little information on the role of the ERK cascade in inflammation. However, 
it was reported that LPS-induced TNF-α production is regulated via an ERK-dependent 
pathway [Dumitru et al., 2000]. Although no direct ERK inhibitors have been reported yet, 
several inhibitors that interfere with the activity of MKKs that act upstream of ERK have been 
described. These compounds including PD 98059 [Dudley et al., 1995] and U0126 [Duncia et 
al., 1998] that are quite effective in inhibiting ERK activation. 
There are four p38 MAPK isoforms, α, β, γ and δ respectively, each encoded by a separate 
gene. The p38α enzyme is the best characterized and is expressed in most cell types. p38 
MAPK was first identified as an IL-1 and LPS activated kinase [Freshney et al., 1994; Han et 
al., 1994]. Therefore, from the very beginning it was expected to play an important role in 
inflammation. Other data that support the role of p38 in inflammatory responses were derived 
from studies with p38 inhibitors such as SB 203580 and SB 239063, which potently inhibited 
the production of proinflammatory cytokines in different cell types [Cuenda et al., 1995; 
Underwood et al., 2000; Barone et al., 2001]. Moreover, administration of SB 203580 was 
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found to have beneficial effects in animal disease models such as collagen-induced arthritis 
and endotoxin induced sepsis-shock [Lee et al., 1999]. p38 MAPKs are also activated by 
many other stimuli including hormones, ligands for GPCRs and stresses such as osmotic 
shock and heat shock [Johnson and Lapadat, 2002]. 
JNKs (JNK 1, 2 and 3) were first isolated and characterized as stress-activated protein kinases 
(SAPKs) due to their activation in response to inhibition of protein synthesis. JNK activity 
can be strongly induced in multiple cell types by proinflammatory stimuli such as LPS, TNF-
α and IL-1 [Davis, 2000; Chang and Karin, 2001]. It was reported that JNKs bind, 
phosphorylate and increase transcription activity of the DNA binding protein c-Jun. c-Jun is a 
component of the activating protein 1 (AP-1) transcription complex, an important regulator of 
gene transcription. AP-1 and related transcription factors such as the activating transcription 
factor 2 (ATF-2) play an important role in inflammatory response due to their ability to 
contribute to the induction of cytokine genes such as those that encode for TNF-α, IFN β and 
IL-6 [Karin, 1995; Chu et al., 1999]. Several different JNK inhibitors have been recently 
identified. One of them, namely SP6000125 has been tested in a rat model of rheumatoid 
arthritis and it was found effective not only in reducing inflammation but also in prevention of 
tissue damage [Han et al., 2001]. 
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1.3. Aim of the study 
 
Several studies suggest a role of sphingolipids in inflammatory responses. However, data 
regarding the possible proinflammatory effects of sphingolipids in a pathological state are not 
available yet. 
A local inflammatory reaction within the intestinal muscularis has been proven to be 
causative for postoperative ileus in both, animal model and human situation. The aim of the 
present study was to investigate the potential involvement of sphingolipids in inflammatory 
processes known to accompany postoperative- and sepsis-induced ileus.  
 
The following questions arise from this aim: 
 
1) Does intestinal manipulation or LPS administration alter sphingolipid composition in rat 
small intestine? 
2) Are sphingolipids able to induce an inflammatory response in primary cultured rat 
intestinal smooth muscle cells (RISM cells), the prevailing cell type in tunica muscularis? 
3) Which is the molecular mechanism underlying the proinflammatory action of 
sphingolipids?  
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2. Materials and Methods 
 
2.1. Materials 
 
Apparatus 
 
Apparatuses   Supplier   Location 
Agarose gel electrophoresis  ComPhor Midi; Biozym Oldendorf 
Analytical balance  BP 210 D; Sartorius  Göttingen 
Autoclave  Fedegari Albuzzano; Italien 
 Varioclave 50050; H+P 
Labortechnik 
Oberschlesien 
 
Balance                           Sartorius  Göttingen 
Bench centrifuge  Centrifuge 5417R; Eppendorf Hamburg 
Blotting Apparatus Mini TransBlot; BioRad München 
Bioflex collagen 1 cuture plate   
Centrifuge Megafuge 2.0 R; Heraeus 
Multifuge 3 S-R; Heraeus
Hanau 
 
Deep freezer (+4°C, -20°C) Robert Bosch GmbH   Geringen- Schillerhöhe          
Deep freezer (-80°C) NapCoil UF 5000; NAPCO Winchester, USA 
Dish washer Mielabor G7783; Miele Köln 
Drying cupboard Heraeus   Hanau 
ELISA-Reader Multiscan Ascent, Dynex Hybaid Frankfurt 
Fluorimeter  Digitalfluorimeter Modell 8-9; 
Locarte, 
Dynex Hybaid Labsystems     
 Frankfurt 
 
Gel  apparatus for SDS-PAGE  Minigel; Biometra 
Multigel-Long; Biometra 
Göttingen 
Gel analysing system AlphaDigiDoc: Biozym Oldendorf 
Heating-agitator Ikamag-Ret; Ika-Labortech  Staufen 
Imager-Plates (Screens) BAS MS 2040 Imaging Plate 
Raytest                       
Straubenhardt 
Incubators Heraeus   Hanau 
Incubation shaker   KS-250 basic; Ika-Labortechnik Staufen 
Laminar flow Biohazard; Gelaire  
Heraeus   
Mailand, Italien 
Hanau 
Microwave   Privileg; ProMarkt Bonn 
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Mixer-mill Retsch Haan 
Peristaltic pump P1; Pharmacia-LKB Freiburg 
Phospho Imager Fujix BAS 1000; Raytest Straubenhardt                         
Photometer    Smart Spec 3000; BioRad München 
Pipettes                                          Eppendorf Research 0,5-10, 10-100, 
1-1000; Eppendorf 
Hamburg 
 
pH-Meter PH 537; WTW Weilheim 
Reacti-Therm III Pierce Chemical Company  Rockford, USA 
Rotator Stuart SUA 
Röntgen cassette Chronex; DuPont de Nemour, France 
Scintillation counter  Packard Tricarb 1600 TR  Rodgau-Jügesheim 
Shaking water bath 1083; Gesellschaft für Labortechnik Burgwedel 
Sonicator Sonorex RK 100, Bandelin Berlin 
Thermocycler PTC-200; MJResearch/Biozym Oldendorf 
Thermomixer Comfort; Eppendorf Hamburg 
Ultrasonicator Sonifer B12 with water cooled 
cup-horn; Branson Sonic Power 
Company   
Danbury, SUA 
Vortexer Bender-Hohlbein  Zürich, Schweiz 
Voltage supply source  Consort; Biometra 
PowerPac 3000; BioRad 
Göttingen 
München 
Water filtration apparatus  EasypureUV/UF; Barnstedt/Werner 
MembraPure; Millipore              
Leverkusen 
Schwalbach 
 
Expendable materials 
 
Items Supplier  Location                             
Cell culture flasks Costar    Cambridge, MA/USA        
Cell scrapers Costar    Cambridge, MA/USA         
Centrifuge tubes, 15 ml Greiner Nürtingen 
Centrifuge tubes, 50 ml Falcon; Beckton-Dickinson Heidelberg 
DC-Plates Kieselgel 60               Merck   Darmstadt 
Disposable Filter Unit Whatman Dassel 
Epis, 1,5/2 ml           Eppendorf           Hamburg 
Filter paper Macherey-Nagel   Düren 
Homo-polymer microtubes, 1.5 
ml, MCT-150-C 
Axygen Scientific Union City, CA, USA 
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Microtiter plates Falcon; Beckton-Dickinson Heidelberg 
Nitrocellulose-Membranes Porablot; Macherey-Nagel  Düren 
Parafilm  AAC   Greenwich, USA 
Petri dishes (8 cm2, 21cm2) Falcon; Beckton-Dickinson Heidelberg 
Pipette tips  Greiner Nürtingen 
Pyrex tubes   VWR   Darmstadt                          
Röntgen films  Kodak Biomax MS-1; Sigma         Taufkirchen 
Scintillation vials: Super 
Polyethylen 
Packard    Frankfurt 
Syringe Beckton-Dickinson Heidelberg 
 
Chemicals 
 
Chemicals   Supplier         Location 
Acetic acid   Riedel de Haen  Seelze 
Acrylamide mixure 37,5:1, 40% Roth   Karlsruhe 
Agarose SMG    AppliChem Darmstadt 
Ammonium hydroxide Merck Darmstadt 
Ammonium peroxodisulfate  Merck   Darmstadt 
1-Butanol  Riedel de Haen   Seelze 
Bovine serum albumin (BSA) Sigma  Taufkirchen 
Calcium Chloride KMF Laborchemie 
Handels GMBH 
Lohmar 
Chloroform   Riedel de Haen Seelze 
Complete Mini, 
EDTA-free Protease Inhibitor 
Roche   Mannheim 
Coomassie-blue R260                         Serva  Heidelberg 
DMSO   AppliChem   Darmstadt 
DEAE-Sephadex A-25 Pharmacia LKB 
Biotechnology 
Uppsala, Sweden 
EDTA  Merck  Darmstadt         
Enhancer ICN  Meckenheim 
Ethanol Riedel de Haen Seelze 
Ethidium Bromide AppliChem Darmstadt 
Foetal bovine serum  PAA Laboratories Pasching, Österreich 
Glycerol Sigma  Taufkirchen 
Glycine Sigma  Taufkirchen 
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HEPES Merck Darmstadt 
Hydrochloric acid, 37%  Riedel de Haen Seelze 
Lipopolisaccaride (LPS) from E. coli 
0111:B4 
Sigma Taufkirchen 
Methanol  Riedel de Haen Seelze 
Potassium chloride   Merck  Darmstadt 
PD98059 (2-(2-Amino-3-
methoxyphenyl)-4H-  
1-benzopyran-4-one   
Biotrend   Köln    
Penicillin/Streptomycin Biomol GmbH  Hamburg 
Potassium dihydrogenphosphate  Merck  Darmstadt 
Roti-Block Roth Karlsruhe 
Roti-Load 1   Roth Karlsruhe 
Silica gel Lichropep RP18 Merck, Darmstadt 
Sodium acetate Merck  Darmstadt 
Sodium azide  Riedel de Haen Seelze 
Sodium chloride  Merck  Darmstadt 
Sodium dodecylsulfate (SDS) Sigma  Taufkirchen 
Sodium desoxycholate Roth  Karlsruhe 
Sodium hydrogenphosphate  Merck   Darmstadt 
Sodium hydroxide Merck  Darmstadt 
Sodium fluoride Merck  Darmstadt 
Sodium  orthovanadate Merck  Darmstadt 
Sodium pyrophosphate Merck  Darmstadt 
N, N, N, N-
Tetramethylethylendiamin 
 (TEMED)   
Roth  Karlsruhe 
Tricin, ultra pure ICN  Meckenheim 
Tris, ultra pure ICN Meckenheim 
Triton X-100 Sigma   Taufkirchen 
Tween-20  Sigma  Taufkirchen 
 
Kits  
 
Kit  Supplier  Location 
CellTiter-Blue Cell Viability Assay Promega   Mannheim 
IL-1α, IL-1β, IL-6 ELISA Kit Biosource Solingen 
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PGE2 EIA Kit  Cayman Chemical, 
IBL-Hamburg 
Hamburg 
Western Blot Chemiluminescence 
Reagent Plus (ECL-Kit) 
Roche    Mannheim 
 
Antibodies, enzymes, proteins 
 
Item Supplier                                  Location      
Cyclooxygenase-2 antibody Santa Cruz Biotechnology Heidelberg 
goat anti-mouse IgG labelled 
with green fluorescent Alexa 
Fluor 488 dye 
Invitrogen  Karlsruhe 
 MultiMark Multi-Colored  
Standard                                    
Invitrogen                Karlsruhe 
Phospho-JNK/SAPK IgG 
antibody 
NEB Frankfurt a M. 
JNK/SAPK IgG antibody NEB Frankfurt a. M 
Phospho-p38 MAPK IgG 
antibody 
NEB Frankfurt a. M 
p38 MAPK IgG antibody Santa Cruz Biotechnology Heidelberg 
phosphor-p44/42 MAPK 
antibody  
NEB Frankfurt a. M 
p44/42 MAPK antibody  NEB Frankfurt a. M 
Peroxidase-conjugated goat-
anti-rabbit-IgG-antibody  
NEB   Frankfurt a. M. 
Peroxidase conjugated goat-
anti-mouse-IgG-antibody  
NEB Frankfurt a. M. 
Pertusis toxin (PTX) Sigma Taufkirchen 
Protein-G-HRP conjugate      Bio-Rad                                  München 
α-tubuline IgG antibody Santa Cruz Biotechnology Heidelberg 
smooth muscle α-actin  
antibody 
Dianova  Dörentrup, Germany 
Recombinant rat IL-1ß, TNF-α Biosource Solingen 
Trypsin/EDTA Cambrex Verviers, Belgium 
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Lipids 
. 
Lipid   Supplier          Location 
Ceramide       Avanti Polar Lipids  Alabaster, USA 
C8 Ceramide-1-phosphate Biomol                                          Hamburg 
C12 Ceramide-1-phosphate  Avanti Polar Lipids  Alabaster,USA 
C18 Ceramide-1-phosphate  Sigma Taufkirchen 
Phosphatidic acid, didecanoyl 
sodium salt  
Sigma   Taufkirchen 
Sphingosin-1-phosphate (S1P) Sigma Taufkirchen 
 
Radioactivity 
 
Item Supplier Location 
[1-14C] Arachidonic acid Amersham Bioscience  Uppsala, Sweden 
[γ-32P]-ATP Amersham Life Science  Freiburg 
 
Media  
 
Medium Supplier Location 
DMEM-F12  Invitrogen, Gibco    Karlsruhe 
MEM  PAA Laboratories Pasching, Austria 
RPMI  Cambrex Bio Science Verviers, Belgium 
 
Solutions and buffers 
 
Anode buffer (SDS-PAGE), pH 8.9 Tris-HCl 200 mM 
APS Ammonium peroxodisulfate  10% (w/v) 
Catode buffer, SDS-PAGE, pH 8.25
  
SDS 
Tricine  
Tris-HCl 
0.1% (w/v) 
100 mM 
100 mM 
Coomassie-blue R260-Stock 
solution 
Coomassie-blue R260 
Ethanol 
85%  Phosphoric acid 
0.05% (w/v) 
25 % 
50% (v/v) 
Copper sulphate reagent 85% Phosphoric acid 
Copper sulfate 
8% (w/v) 
10% (w/v) 
EDTA Solution, pH 8.0  EDTA (Dinatriumsalt)   500 mM 
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3 x Gel buffer, pH 8.45 SDS 
Tris-HCl 
0.3% (w/v) 
3 M 
Glycin-Strip buffer, pH 2.2  Glycin  
SDS 
Tween-20 
0.2 M 
0.1% (w/v)  
1% (v/v) 
HBSS (Hanks balanced salt 
solution) 
Perbio Science  Bonn 
Germany 
Homogenization buffer, pH 7.4 
(buffer A) 
phosphate buffer  
glycerol 
mercaptoethanol 
EDTA 
sodium orthovanadate 
sodium fluoride 
leupeptin and aprotinin 
PMSF(phenylmethylsulfonylfluoride)   
4-deoxypyridoxine  
0.1 M 
20% 
1 mM 
1 mM 
1 mM 
1 mM 
10 µg/ml 
1 mM 
0.5 mM 
Lysis buffer, pH 7.4 Complete Mini, EDTA-free 
Protease-Inhibitor 
Desoxycholate, 5 % Stock solution 
EDTA  
β-Glycerophosphate 
HEPES, pH 7.4   
NaCl             
Sodium flouride 
Sodium pyrophosphate 
orthovanadate 
SDS 10% stock sol. 
Triton X-100, 10% stock sol.    
1 Tbl./10 ml 
 
10% (v/v) 
2 mM 
50 mM 
20 mM 
100 mM 
10 mM 
10 mM 
2 mM 
10%(v/v) 
10 % (v/v) 
PBS (Phosphate Buffered Saline) KCl 
KH2PO4 
NaCl             
Na2HPO4             
3 mM 
1,5 mM 
140 mM 
16 mM 
Reaction buffer (buffer B) Tris buffer pH 7.4 
glycerol  
EDTA 
mercaptoethanol  
sodium orthovanadate 
30 mM 
5% 
0.25 mM 
1 mM 
1 mM 
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sodium fluoride 
leupeptin , aprotinin 
4-deoxypiridoxine 
PMSF  
15 mM 
10 µg/ml 
0.5 mM 
1 mM 
Resolving gel, 10 %, 15 ml sol. 3 x Gel buffer    
Acrylamide mix 37,5: 1, 40%  
Glycerol    
H2O     
APS 10%  
TEMED  
6.75 ml 
3.75 ml 
2.1 ml 
2.25 ml 
15 µl 
30 µl 
Ringer solution Baxter, Deerfield, III USA 
Stacking gel, 4 %, 7.5ml 3 x Gel buffer 
Acrylamide mix 37.5: 1, 40%                
H2O 
APS 10% 
TEMED    
3.415 ml 
750 µl 
2.85 ml 
15 µl 
70 µl 
SDS-stock solution   SDS    10% (w/v) 
S1P-stock solution S1P, in Methanol 1.3 mM 
50 x TAE, pH 8.0  EDTA 
Tris-Acetate     
50 mM 
2 M 
TBS Blotto A  Non-fat dry milk 
Tween-20     
5% 
0.05% 
TBST, pH 7.6   Sodium chloride  
Tris-HCl    
Tween-20    
137 mM  
20 mM 
0.1% (v/v) 
Transfer buffer, Western Blot, pH 
8.5 
Tris-Base 
Glycin     
Methanol    
25 mM  
200 mM  
20% (v/v) 
Triton X-100-stock solution  Triton X-100 10% (v/v) 
Vanadate stock solution  Sodium orthovanadate, activated
  
200 mM 
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2.2. Methods 
2.2.1. Animals 
 
Male Sprague-Dawley rats (200-250 g) were obtained from Harlan Winkelman (Borchen, 
Germany). Rats were subjected to surgical manipulation that involved the compression of the 
small intestine. These experiments were performed at the Klinik und Poliklinik für 
Allgemein-, Viszeral, -Thorax- und Gefässchirurgie of University of Bonn by Dr. Sven 
Wehner. Animal experiments followed institutional guidelines and were performed after 
approval of local ethics committees at University of Bonn. All animals were maintained on a 
12-hour light/dark cycle with nutrition and tap water offered ad libitum. 
2.2.1.1. Surgical manipulation model of rat small intestine 
 
The small bowel of the animals was subjected to a nontraumatic intestinal manipulation 
according to standardized protocols [Kalff et al., 1998]. Rats (Stamm Wistar, SD, Lewis; 17 
days old or younger) were anesthetized by inhalation anaesthesia, and a midline incision was 
made into the peritoneal cavity. The small bowel was eviscerated to the left onto a moist 
cotton gauze pad, and the entire small bowel was lightly manipulated with two moist cotton 
applicators. The operative procedures were performed under sterile conditions. Non-operated 
animals served as controls. In the time-course study, 3 groups of 5 animals were evaluated, 
each at a different time point (3, 6, 12, and 24 h) after intestinal manipulation.  In all groups, 
the operative time was similar, and the midline incision was closed by two-layer continuous 
sutures. The animals recovered from the procedure within 10 min. Small-bowel preparations 
from these animals were used for sphingolipid extraction. 
2.2.1.2. In vivo induced endotoxemia 
 
Endotoxemia was induced by bolus intraperitoneal injection of LPS (10 mg/kg). Rats were 
killed at various time points (3, 6, 12 and 24 h) after treatment for analysing the sphingolipid 
composition of the small intestinal tissue [Eskandari et al., 1997]. 
2.2.1.3. Small-bowel preparation 
 
Animals were anesthetized at sacrifice and small-bowel specimens were harvested as 
described previously [Kalff et al., 1998]. The abdominal wound was reopened and the 
abdominal aorta cannulated and flushed with 3 ml of cold (4°C) Ringer solution. This flush 
was used to remove non-adherent and non-extravasated blood cells from the muscularis 
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vasculature. The entire small bowel was then removed and placed in cold pre-oxygenated 
Krebs-Ringer buffer (KRB). The small bowel was used for the selective isolation of the 
muscularis and mucosa layers. The entire small bowel was cut in 4- to 5-cm segments. Each 
segment was sequentially pinned down in a dissecting Sylgard dish containing chilled Hanks 
balanced salt solution (HBSS) to remove the mesenteric tissue before it was slipped onto a 
glass rod. A knitting needle with adequate size was inserted into each portion of intestine and 
carved along the mesenterium with a fine tweezers, cautiously not to damage the muscle 
layer. The muscularis was incised carefully along the mesentery and stripped of the mucosa 
by circumferentially peeling off the muscularis with a moist cotton applicator and placed in a 
glass filled up with chilled HBSS. The isolated layers were frozen in liquid nitrogen and 
stored at -80°C until tissue extraction. Mucosa and muscularis layers were used for lipid 
analysis. 
2.2.2. Cell culture 
2.2.2.1. Isolation of rat intestinal smooth muscle cells 
 
Muscle strips were cut into very small pieces and transferred in a falcon tube filled up with 
HBSS. After they settled down, the HBSS was removed and a mixture of enzyme containing 
0.6 mg/ml Collagenase Typ II, 2 U/ml Dispase II in 8 ml of HBSS was added.  Strips were 
incubated at 37°C for 45 min in a shaking water bath at 120-140 rpm. After centrifugation for 
5 min at 300 x g, the supernatant was discarded and the pellet was resuspended in 10 ml 
HBSS. Rat intestinal smooth muscle (RISM) cells dispersed from the muscularis layer were 
harvested by filtration through 500 µm Nitex mesh and centrifuged at 300 x g for 5min. Cells 
were resuspended and washed twice by centrifugation at 300 x g for 5 min. After 
resuspension in 5 ml of RPMI medium, 3 ml of Accuspin were added carefully for density 
gradient centrifugation, performed for 20 min, 800 x g, 4°C, and swing out 1/1. In the 
meantime the culturewares were coated with a thin film of serum and placed in the incubator 
at 37°C.  
After gradient centrifugation, two phases and a pellet containing muscle cells were obtained. 
The pellet containing smooth muscle cells was transferred to a new 15 ml falcon tube. Cells 
were washed twice with 5 ml of RPMI by centrifugation at 300 x g, 5 min. The pellet was 
resuspended with 3 ml of Dulbeccos Modified Eagle Medium (DMEM-F12) medium. Cells 
were counted using trypan blue solution in 1:1 ratio with cell suspension. Cells were 
incubated in a 10% CO2 atmosphere at 37°C. 
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Culture medium (DMEM/F12 + 10% fetal calf serum + 1% Pen/Strep) was changed every 
three days until the cells reached confluence. The cells were used in an early passage because 
after 5-6 passages they differentiate to fibroblasts or myofibroblasts. 
2.2.2.2. Splitting of smooth muscle cells 
 
When a postconfluent density was reached, the cell culture was split 1:3 1:5 in 75 cm2 flasks 
by removing the culture medium, washing the cell monolayer with warmed Phosphate Buffer 
Saline (PBS) and pipetting 2-3 ml (0.05% / 0.02%) of Trypsin/EDTA for 2-3 min. During that 
time, the flask was placed in the incubator and the cells were examined microscopically to 
ensure that all of them were detached and floating. The side of the flask was gently tapped to 
release any remaining attached cells. The trypsin was inactivated with 5 ml of culture medium 
and the cell suspension was pelleted for 5 min at 300 x g. The supernatant was removed, the 
cells resuspended in culture medium and added to flasks (75 cm2) containing 15 ml of 
medium. 
2.2.2.3. Storage of smooth muscle cells 
 
After splitting the cells (trypsinization and centrifugation), the pellet was resuspended in 2 ml 
of foetal calf serum (FCS) and 2 ml of cell culture freezing medium (serum free medium 
DMEM-F12 with 10% DMSO). Cell suspension was aliquoted into appropriate cryogenic 
storage vials (2 ml/vial) and placed at -80°C for 24 h and then in liquid nitrogen (-196°C). 
2.2.2.4. Treatment of smooth muscle cells with sphingolipids and other 
compounds 
 
Confluent cells from 75 cm2 flasks were harvested as described above and placed in 8 cm2 or 
21 cm2 dishes. The dilution of the cells was adjusted to achieve approximately 80% 
confluency at the time of treatment. Experiments were performed in Modified Eagle Medium 
(MEM) supplemented with 0.3% FCS and 1% Pen/Strep. At the day of treatment, the culture 
medium was removed, the cell monolayer was washed twice with the new medium and the 
cells were incubated for different time periods with medium containing methanol (as control) 
or different sphingolipids. The final concentration of shingolipids in medium was 1, 5 or 10 
µM. S1P was added to the medium as complex with bovine serum albumin (BSA) (4 mg/ml). 
The complex was formed by incubating the BSA-medium with S1P for 30 min at 37ºC. In 
some experiments the cells were preincubated for 30 min with medium containing inhibitors 
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of the signal transduction cascade components (ERK, p38 MAPK, receptor coupled Gi/0-
protein) prior to being treated with sphingolipids.  
At different time intervals after treatment, the cells were harvested with a cell scraper in 500 
µl of PBS (4ºC) after removing the medium and washing twice with cold PBS. The cell 
suspension was pelleted at 2000 x g for 10 min, 4 ºC and cell pellets were stored at -37 ºC 
until their subsequent use. 
2.2.2.5. Immunocytochemistry 
 
For immunofluorescence experiments, cells were plated on glass coverslips for up to 72 h. 
When cells were 50-70% confluent, the culture medium was removed, and the cells were 
thoroughly washed with pre-cooled PBS. The pre-washed cells were fixed with cold methanol 
for 10 min at -20°C. Fixed cells were washed three times with PBS to remove any solvent 
traces and the reaction was blocked by incubation in PBS containing 3% BSA for 1 h at room 
temperature. Cells were washed one time with 0.3% PBS/ BSA and then incubated overnight 
at 4°C with a smooth muscle α-actin primary antibody (1:100). Coverslips were washed three 
times with PBS and then incubated for 1 h at room temperature with secondary antibody, goat 
anti-mouse IgG labelled with green fluorescent Alexa Fluor 488 dye. Immunoreactive protein 
was visualized by fluorescence microscopy. 
2.2.2.6. Application of mechanical stretch to smooth muscle cells 
 
RISM cells were seeded into 6-well type 1 collagen-coated, silicone elastomer-base culture 
plates. The cells grown to confluence on the flexible surface were subjected to cycles of 
stretch and relaxation using a computer-driven, vacuum-operated, stress-providing instrument 
(Flexercell Strain Unit FX-4000 Tension plus; Flexcell Interational). The vacuum induced 
20% elongation in the diameter of the flexible surface with sinus shapes. The cells were 
exposed to stretch for 2 x 30 min (0.5 Hz) 5 min break in between. Mechanical stretch was 
performed in a humidified incubator with 5% CO2 and 37°C. Control cells were grown in 
nondeformable plates in parallel. Cells were examined by phase-contrast microscopy to verify 
cell attachment.  
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2.2.3. Lipid analysis by thin layer chromatography 
2.2.3.1. Extraction of lipids from tissues 
 
Tissue samples collected after gentle manipulation of the small bowel were provided by Prof. 
Jörg Kalff from Department of Surgery, University of Bonn and stored at -80°C. Before 
starting the procedure, an appropriate amount of intestinal tissue was weighted (about 50 mg 
wet weight from mucosa layer and 25 mg wet weight from muscularis layer, respectively). 
The samples were homogenized with 600 µl of water (bi-distilled water) using a Mixer-mill. 
Homogenates were transferred to glass tubes and lipids were extracted with 2 ml of methanol 
and 1 ml chloroform for 48 h at 40ºC. After extraction, tissue debris were spinned down by 
centrifugation at 2000 rpm for 10 min at room temperature and the upper phase was filtered 
through glass Pasteur pipettes filled with cotton wadding. The pellet was extracted again with 
700 µl water and 3 ml of chloroform/methanol (1:2; v/v) by strong vortexing for 30 sec. The 
upper phases were pooled and the solvent was evaporated under a stream of nitrogen at 37 °C. 
2.2.3.2. Extraction of lipids from smooth muscle cells 
 
The cell pellet was homogenized in 400 µl of water and at this step aliquots were taken for 
protein determination. Total lipids were extracted with 5.85 ml of chloroform/methanol (2:1; 
v/v) for 24 h at 48°C. After extraction, denaturated particles were removed by passing the 
samples through glass Pasteur pipettes filled with cotton wadding, used as filtration columns. 
Prior to application of the lipid extract, the wadding filter was rinsed with 1 ml of extraction 
solvent chloroform/methanol/water (10:5:1 v/v/v). The filter sample was collected in a new 
screw-capped Pyrex tube with Teflon inlay placed under the pipette tip. Finally, the wadding 
filter was rinsed with 2 ml of extraction solvent that was collected in the same tube. The 
solvent was evaporated under a stream of nitrogen at 37°C [van Echten-Deckert, 2000].  
2.2.3.3. Removal of lipid contaminants 
 
Phospholipids, the major lipid components of the biological membranes comigrate with 
different sphingolipid species during their separation by thin layer chromatography (TLC). 
Therefore they were removed from the cellular lipid extracts by mild alkaline methanolysis 
(saponification). Extracts were dissolved in 2.5 ml of methanol and sonicated for 5 min in a 
sonifier. Then, 62.5 µl of NaOH (4 M stock solution in water) were added to a final 
concentration of 100 µM. After shaking for 2 h at 37ºC, samples were neutralized by addition 
of 10 µl of concentrated acetic acid. Finally, the solvent was evaporated as described above. 
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2.2.3.4. Reversed-phase chromatography 
 
Small hydrophilic molecules such as salts, amino acids, sugar, small peptides are extracted 
along with sphingolipids, as well as salts formed by addition of NaOH, interfere with lipid 
behaviour during separation by TLC. The polar nonlipid contaminants were removed by 
reversed-phase chromatography [van Echten-Deckert, 2000]. 
2.2.3.4.1. Preparation of gel 
 
Silica gel RP18 (particle size 40-63 µm) was suspended in chloroform-methanol (2:1, v/v) 
and cautiously shaken for 30 min. The silica gel was allowed to settle and after removing the 
supernatant, the silica gel was resuspended in methanol (1:1, v/v), shaken carefully for 30 
min, and the supernatant was poured off again. This step was repeated 3-4 times with fresh 
methanol. The suspended gel was stored in methanol at 4 ºC. 
2.2.3.4.2. Chromatography 
 
A small piece of fibre wadding was introduced into glass Pasteur pipettes and 2 ml of the 
silica gel RP18 suspension was added. The columns were rinsed two times with 1 ml of 
chloroform/methanol/0.1 M potassium chloride (6:96:94, v/v/v). The samples (lipid extracts) 
were dissolved in 1 ml of methanol and sonicated for 5 min. Then 1 ml of ammonium acetate 
(300 mM in water) was added to each sample. 
The samples were applied onto the columns. The empty sample tubes were rinsed two times 
with 0.5 ml of ammonium acetate (200 mM in methanol/water, 1:1, v/v) and applied to the 
columns. The bulk of polar contaminants remained in the flow-through fraction. The columns 
were washed with 6 ml of water (doubly distilled quality) to elute all polar contaminants.  
New tubes were placed under each column for collecting the lipid fraction. The lipids were 
eluted with 1 ml of methanol and with 8 ml of chloroform-methanol (1:1, v/v). The samples 
were dried by evaporating the solvent under a stream of nitrogen. 
2.2.3.5. Anionic-exchange chromatography 
 
Anionic glycosphingolipids, such as gangliosides and sulfatides, can be separated from 
neutral glycosphingolipids, sphingomyelin, and ceramide by anionic-exchange 
chromatography. In this way, comigration of anionic and neutral glycosphingolipids on the 
same TLC can be avoided. 
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2.2.3.5.1. Preparation of resin 
 
DEAE-Sephadex A-25 was used in our study. For stability reasons the resin was delivered in 
its chloride form and had to be converted to the acetate form. 
DEAE-Sephadex was let to swell overnight in distilled water (10 g in 150 ml). The 
supernatant was discarded by filtration using a Chinese funnel and filter paper. The resin was 
washed again with distilled water and then with 1 M sodium acetate in water until the 
supernatant was devoided of chloride anions. This was tested by acidification of the discarded 
supernatant with silver nitrate. Conversion of DEAE-Sephadex to the acetate form was 
completed when no silver chloride precipitate was formed in the supernatant. The DEAE-
Sephadex in its acetate form was stored in methanol (1:1) at 4ºC. 
2.2.3.5.2. Chromatography 
 
Small pieces of cotton wadding were introduced into glass Pasteur pipettes and 2 ml of 
DEAE-Sephadex suspension were added. The columns were then washed with 1 ml of 
methanol and 3 times with 1 ml of chloroform/methanol/water (3:7:1, v/v/v). A new tube was 
placed under each column for collection of the neutral lipids. The samples were dissolved in 1 
ml of solvent chloroform/methanol/water (3:7:1, v/v/v) and sonicated for 1 min in an 
ultrasonifier. 
The samples were applied to the columns and the empty sample tubes were rinsed two times 
with chloroform/methanol water (3:7:1, v/v/v) and applied to the columns. Neutral lipids were 
eluted with 3 ml of chloroform/methanol/water (3:7:1, v/v/v) and after evaporating of the 
solvent this lipid fraction was ready for TLC. New tubes were placed under each column for 
collection of the anionic lipid fraction. Anionic lipids were eluted with 8 ml of 
chloroform/methanol/0.8 M ammonium acetate (3:7:1, v/v/v). The anionic lipid fractions were 
dried and salts were removed by reversed-phase chromatography as described above. 
2.2.3.6. Thin layer chromatography 
 
Glass-backed silica gel 60 precoated TLC plates were used for sphingolipid thin layer 
chromatography (TLC). Samples (maximal volume 50 µl) were applied as 0.5-to 1-cm bands 
on the TLC plate using small glass capillaries. Solvent systems (mixtures of 
chloroform/methanol/water or aqueous salts) used for development of chromatograms were 
freshly mixed and added to the tank allowing the formation of the vapour-liquid equilibrium 
for at least 60 min. 
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For TLC separation of most sphingolipids we used the following solvent system: 
chloroform/methanol/0.22% aqueous CaCl2, (60:35:8, v/v/v). For a good resolution of 
ceramide, the TLC plate was run twice consecutively in chloroform/methanol/acetic acid 
(190:9:1, v/v/v). Neutral sphingolipids (sphingomyelin, lactosylceramide, ceramide, 
cholesterol) were resolved using the solvent system: chloroform/methanol/2 M aqueous 
ammonia (65:25:4, v/v/v). 
2.2.3.7. Visualization and quantitative determination of sphingolipids on 
TLC 
2.2.3.7.1. Autoradiography 
 
Cellular sphingolipids biosynthetically labelled with L-[3-14C]serine were detected and 
evaluated on TLC plates with the bioimaging analyser Fujix Bas 1000 using the software 
TINA 2.09 (Raytest, Straubenhardt, Germany). 
2.2.3.7.2. Staining 
 
For visualization of non-radioactive sphingolipids we used cupric sulphate in aqueous 
phosphoric acid. The TLC plates were sprayed heavily until they appeared wet. Then the 
plates were heated in an oven at 180ºC for about 15 min. Lipid bands obtained by TLC were 
evaluated by photodensitometry (Shimadzu, Kyoto, Japan). 
2.2.4. Lipid analysis by mass spectrometry 
 
Sphingolipids from rat small bowel tissue (mucosa and muscularis layers) were analysed by 
high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) in 
laboratory of Professor Alfred H. Merrill Jr. at Georgia Institute of Technology (Atlanta, 
USA) according to a standard protocol [Sullards and Merrill, 2001]. 
The internal standards for the mass spectrometric analyses were:  C17-sphingosine (d17:1), 
C17-sphingosin-1-phosphate, C17-sphinganine-1-phosphate, C12-ceramide (N-dodecanoyl-
sphingosine, d18:1/12:0), C12-Ceramide-1-phosphate and C12-sphingomyelin.  The internal 
standards were prepared as 1 mM stocks in ethanol that were mixed to produce a cocktail 
containing each compound at 50 µM (to deliver 500 pmol in 10 µl). These stocks could be 
stored for at least several months when stored in microfuge tubes (1.5 ml Homo-polymer 
microtubes) and were checked periodically for losses and replaced when needed. 
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2.2.4.1. Extraction of samples 
 
Prior to extraction, tissues were weighed, homogenized in ice cold PBS, transferred into 13 x 
100 mm borosilicate screw cap test tubes with Teflon caps and frozen-dried/lyophilized in 
triplicates. The aqueous volume at this stage was 0.1 to 0.2 ml.  After adding 0.5 ml of 
methanol and internal standards (in 10 µl), the lipids were dispersed using a bath type 
sonicator at room temperature for 30 sec, 0.25 ml of chloroform were added, and the capped 
tubes were incubated at 48°C overnight in a heating block.  After cooling, 75 µl of 1 M KOH 
in methanol were added, mixed briefly by sonication, incubated in a heating block for 2 h at 
37°C, and clarified by centrifugation.  For analysis of sphingoid bases and related compounds, 
0.4 ml was removed and transferred to a new test tube and the solvent was evaporated under 
vacuum at room temperature (in a Savant Speedvac). The lipids were redissolved afterwards 
by sonication of the mobile phase for reversed-phase chromatography, centrifuged to clarify 
and transferred to autoinjector vials.  The remainder of the extract was neutralized with 3 µl 
of glacial acetic acid, and 1 ml of chloroform and 2 ml of water were added. The samples 
were mixed and then centrifuged, the lower layer was collected with care to recover the 
interface, transferred to a new test tube, and the solvent was removed under vacuum at room 
temperature. In the end, the lipids were redissolved in the mobile phase for normal phase 
chromatography with sonication, centrifuged to clarify and transferred to autoinjector vials. 
2.2.4.2. High Performance Liquid Chromatography Tandem Mass 
Spectrometry  
 
Sphingoid bases and 1-phosphates (including ceramide-1-phosphate) were separated by 
reverse-phase HPLC using a binary system (Perkin Elmer Series 200 MicroPump) and a 
Supelco 2.1 mm i.d. x 5 cm Discovery C18 column and a flow rate of 1 ml/min. Mobile phase 
A consisted of methanol/water/formic acid (58:41:1, v/v/v); mobile phase B consisted of 
methanol/formic acid (99:1, v/v); both also contained 5 mM ammonium formate.  For each 
analysis, the column was equilibrated with 60:40 (A: B) for 0.4 min, the sample was injected 
(50 ml by a Perkin Elmer Series 200 Autosampler) and 60:40 (A: B) was continued for 0.5 
min, followed by a 1.8-min linear gradient to 100% B, which was held for 5.3 min and then 
the column was re-equilibrated at initial conditions for 0.5 min. 
Complex sphingolipids (ceramide, sphingomyelin) were separated by normal phase 
chromatography using a Supelco 2.1 mm i.d. x 5 cm LC-NH2 column and a flow rate of 1.0 
ml/min.  Mobile phase A consisted of acetonitrile/methanol/acetic acid (97:2:1, v/v/v); mobile 
phase B consisted methanol/water/n-butanol/acetic acid (64:15:20:1, v/v/v/v); both also 
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contained 5 mM ammonium acetate. For each analysis, the column was equilibrated with 98:2 
(A: B) for 0.5 min, the sample was injected, and 98:2 (A: B) was continued for 1.1 min, 
followed by a 0.2 min linear gradient to 82% A.  This state was held for 0.4 min, followed by 
a 0.8 min linear gradient to 100% B, and re-equilibration of the column at initial conditions 
for 0.5 min.  
 The mass spectrometry data was collected using a PE Sciex API 3000 triple quadrupole mass 
spectrometer equipped with a turbo ion-spray source.  Dry N2 was used as the nebulizing gas 
at a flow rate of 6 l/min.  The ion spray needle was held at 5500 V, and the orifice and ring 
voltages were kept low (30-40 V and 180-220 V, respectively) to minimize collisional 
decomposition of molecular ions prior to entry into the first quadrupole, and the N2 drying 
gas temperature was set to 500 °C.  N2 was used to collisionally induce dissociations in Q2, 
which was offset from Q1 by 30-40 V.  Q3 was then set to pass molecularly distinctive 
product ions. A multiple reaction monitoring method (MRM) has been developed for the 
typical fatty acyl chain length variants for these mammalian sphingolipids (i.e., C16:0, C18:0, 
C20:0, C22:0, C24:1, C24:0, C26:1 and C26:0), including the variants with a 4-
hydroxysphinganine backbone [Merrill et al., 2005]. With the typical number of subspecies 
for each compound, each transition had a dwell time of ~25 ms. After building the MRM 
protocol, the intensities of the signals for the different sphingolipid subspecies were compared 
with the internal standards to arrive at estimations of the mass that are usually within + 10%. 
Quantitative analysis was based on calibration curves constructed by plotting the peak area 
ratios of analyte to the respective internal standard against concentration using a linear 
regression model. The target analyte peak area ratios from the samples were normalized to the 
respective internal standard and compared with the calibration curves. 
2.2.5. Sphingosine kinase activity assay 
 
For sphingosine kinase assay, RISM cells were washed and scraped in cold PBS. After 
centrifugation, the cell pellet was homogenized in 50 µl of phosphate buffer, pH 7.4 (buffer 
A) and cells were disrupted using a mixer-mill.  For subsequent assays, the cell pellets were 
stored at -80ºC without loss in sphingosine kinase activity.  
For studies of sphingosine kinase activity, 70-100 µg proteins were used, with or without 
sphingosine (50 µM) delivered as sphingosine-BSA complex. The reaction mixture contained 
Tris buffer, pH 7.4 (buffer B) in a final volume of 200 µl. Reactions were started by addition 
of 10 µl of ATP in MgCl2 (100 mM), [γ32 P] ATP (1-2 µCi, 20 mM), and incubated for 30min 
at 37ºC in a shaking bath. Reactions were stopped by adding 20 µl of 1 N HCl followed by 
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0.8 ml of chloroform/methanol/HCl (100:200:1, v/v/v). After vigorous vortexing, 240 µl of 
chloroform and 240 µl of 2N KCl were added and the phases were separated by 
centrifugation. The labelled lipids in the organic phase were resolved by TLC on silica gel 
G60 with 1-butanol/methanol/acetic acid/water (80:20:10:20, v/v/v/v) and visualized by 
autoradiography. The radioactive spots corresponding to authentic S1P were identified using 
S1P as standard. 
2.2.6. Quantification of arachidonic acid release 
 
Cells were labelled overnight with 0.2 µCi /ml of [14C] arachidonic acid in culture medium. 
Then medium was removed, cells were rinsed three times with culture medium and then 
incubated in 1 ml of medium containing the desired additives. After incubation for the 
indicated times, the medium was removed and an aliquot was submitted to scintillation 
counting. Results were normalized to cell protein. In addition, media were subjected to 
reversed-phase chromatography as described above (see section 2.2.3.4). The samples were 
applied on Silicagel-60 TLC-plates developed with n-hexane/diethyl ether/glacial acetic acid 
(70:30:1, v/v/v). Arachidonic acid was visualized by autoradiography using the bio-imaging 
analyzer Fujix bas 1000 software, Tina 2.09, (Raytest, Straubenhardt, Germany). 
2.2.7. Immunoblotting 
2.2.7.1. Preparation of protein samples 
 
The cell pellets were resuspended in 100 µl of lysis buffer (4°C) (see section 2.1), incubated 
for 10 min on ice and shortly sonicated for 20 sec at 60 W. Cell debris were spinned down by 
centrifugation for 10 min, at 10000 x g, 4°C. The cell lysates were transferred to new 
eppendorf tubes and the concentration of protein was determined with Bradford method as 
described in section 2.2.7.2. The cell lysates were stored at -80°C until their subsequent use. 
For Sodium dodecylsulfate-Polyacrylamide gel electrophoresis (SDS-PAGE), a 
corresponding amount of cell lysate (as calculated after protein determination) was treated 
with a reducing SDS-containing buffer (RotiLoad 1) and heated up for 10 min at 95°C in a 
thermomixer. To separate the proteins, 10-20 µg of sample were applied to SDS-PAGE. 
2.2.7.2. Quantitative measurement of protein concentrations 
 
The protein concentration was determined with the Bradford method in a microtiter plate. 
This method is based on the blue stain of Coomassie blue in acidic solution upon reaction 
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with protein. A standard curve for BSA was calculated from the absorptions obtained from 10 
standard solutions ranging from 0 to 250 µg/ml.Always, 20 µl of standard or protein sample at 
varying dilutions were added to 200 µl of Bradford reagent (Coomassie-Blue R250) diluted 
1:5 in Millipore water. The microtiter plate was incubated for 10 min in the absence of light 
and the absorption measurements (595 nm) and calculation of sample concentrations were 
carried out photometrically on a Multiskan Ascent readout instrument. 
2.2.7.3. SDS-PAGE 
 
Proteins were separated on a 10% running gel and a 4% stacking gel according to Schägger-
Jagow [Schagger and von Jagow, 1987]. Electrophoresis was performed in 8 x 9 cm vertical 
gels of 1 mm thickness in a Minigel apparatus. Gels were run at 60-120 V and in cool 
conditions to avoid the smiling effect of protein bands due to overheating. 
2.2.7.4. Western Blotting 
 
After SDS-PAGE, the proteins were transferred to a nitrocellulose membrane by wet blotting. 
Before blotting, the nitrocellulose membrane was soaked in transfer buffer. The membrane 
was placed on the gel and covered with filter paper and sponge pads, both soaked in transfer 
buffer. The assembly was enclosed in the blotting apparatus filled with cooled transfer buffer. 
Blotting was performed for 2 h at 250 mA. After the protein transfer, the membrane was 
saturated with 5% non-fat dry milk in Tris-Buffered Saline Tween-20 (TBST) or with 1x 
RotiBlock for 1 h at room temperature. For protein identification, the membrane was 
incubated in a solution containing appropriate primary antibody, overnight at 4°C, on a 
rotator. After incubation, the membrane was washed 3 times for 10 min each, with TBST and 
incubated with the appropriate secondary antibody (anti-mouse-HRP 1:10000, anti-rabbit-
HRP 1:10000, protein G-HRP-conjugate 1:10000) in TBST for 2 h at room temperature. After 
further washing steps in TBST, the membrane was incubated for 1 min with 1.5 ml of 
enhanced chemiluminescence reagent. The chemiluminescence of the secondary antibody was 
detected by a photographic film (10 sec to 3 min depending on the chemiluminescence 
intensity). The same membrane was used to identify proteins that are constitutively expressed 
in the cells in order to confirm equal amounts of protein loaded for each sample. For that, the 
blots were stripped twice for 15 min with Glycin-stripping buffer to remove the bound 
antibodies. After washing 2 times, 10 min each, with TBST and after blocking, the membrane 
was reprobed with an antibody specifically recognizing total (phosphorylated and 
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unphosphorylated) MAPKs or α-tubulin for membranes first treated with cyclooxygenase-2 
antibody. 
 
Primary antibody            Donor              Dilution 
Anti-cyclooxygenase-2            goat       1:400 in TBSBlottoA 
Anti-phospho-p38 MAPK            Rabbit       1:1000 in TBST 
Anti-p38 MAPK            Rabbit       1:1000 in TBST 
Anti-phospho-p44/42 ERK            Rabbit       1:1000 in TBST 
Anti-p44/42 ERK            Rabbit       1:1000 in TBST 
Anti-phospho-JNK/SAPK            Rabbit       1:1000 in TBST 
Anti-JNK/SAPK            Rabbit       1:1000 in TBST 
Anti-α- tubulin            mouse       1:5000 in TBST 
 
2.2.8. Enzyme Linked-Immuno-Sorbent Assay  
2.2.8.1. Prostaglandin E2 assay 
 
Cells were seeded in 8 cm2 dishes and treated with sphingosine-1-phosphate or ceramide-1-
phosphate as described in section 2.2.2.4. At different time intervals, media were collected 
and centrifuged at 1000 g x 5 min to remove detached cells and stored at -80 ºC for 
subsequent PGE2 determination. A 1:20 dilution ratio was optimal for analysis. Secreted 
PGE2 was assayed using the Prostaglandin E2 monoclonal enzyme immunoassay (EIA) kit. 
This assay is based on the competition between PGE2 presented in the media and a PGE2-
acetylcholinesterase (AChE) conjugate (PGE2 Tracer) for a limited amount of PGE2 
monoclonal antibody. The antibody-PGE2 conjugate binds to a goat anti-mouse antibody 
previously attached to the wells (Fig. 7). The plate is washed to remove any unbound reagent 
and then Ellmans reagent (which contains the substrate to AChE) is added to the wells. The 
product of this enzymatic reaction has a yellow colour and absorbs strongly at 412 nm. The 
concentration of PGE2 present in a sample is inversely proportional to the yellow colour 
produced. The concentration of PGE2 was calculated using a standard curve prepared with 
known concentrations of PGE2. Samples were assayed in triplicate for each condition. 
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Fig. 7 Scheme of the PGE2 enzyme immunoassay.    - goat monoclonal anti-mouse IgG;    -PGE2 monoclonal 
antibody;          -acetylcholinesterase linked to PGE2 (Tracer);     -PGE2 
2.2.8.2. Cytokine assays 
 
Cytokines released in cell culture media (IL-1β, IL-6) were measured using the respective 
ELISA kits. After treatment with S1P, TNF-α or LPS, cultured media were collected and 
centrifuged to remove detached cells and stored at -80ºC for subsequent cytokine 
determination. ELISA for rat IL-1ß, IL-6 was performed according to the manufactures 
instructions. These assays utilize an immobilized rat IL-1ß or IL-6 antibody, a biotinylated 
antibody specific for rat IL-1ß or IL-6, horseradish peroxidase-conjugated streptavidin and 
tetramethylbenzidine (TMB) as the peroxidase substrate. The optical density was determined 
using a Multiskan microplate reader set at 450 nm (Fig. 8) and the concentration of the 
respective cytokine was calculated using a standard curve prepared with known 
concentrations of recombinant rat IL-1ß or IL-6. Samples were assayed in triplicate for each 
condition. 
 
 
 
 
 
 
 
 
Fig. 8 Scheme of the cytokines enzyme immunoassay.    -IL-1ß, IL-6-antibody;       -IL-1ß or IL-6 ;   - biotin-
labelled anti-IL-1 or IL-6;       -streptavidin-peroxidase (HRP) 
 
2.2.9.  Statistics 
 
Data were complied as mean ± standard deviation of the mean. Statistical analysis was 
performed using GraphPad Prism 3.03 software (GrapfPad Software Inc. California, USA) 
with a significant level of *p<0.05. **p<0.01 
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3. Results 
 
3.1. Standardized in vivo animal model of small intestinal manipulation 
 
It has been previously shown that surgical manipulation of the rat small intestine elicits an 
inflammatory response within the tunica muscularis externa accompanied by suppression of 
smooth muscle layer contractility and hence a decresed intestinal transit. For those studies, a 
standardized surgical rodent model of small intestinal manipulation was established [Kalff et 
al., 1998]. Rats were subjected to progressive degrees of gentle surgical manipulation that 
involved compression of the small intestine to mimic normal abdominal operative procedures. 
In rats the small intestine is said to serve as a good model for postoperative ileus [Luckey et 
al., 2003]. To investigate the potential role of sphingolipids in postsurgical ileus, we used this 
animal model. As a result of intestinal manipulation, functional alterations of rat small 
intestine might be reflected by changes in the levels of sphingolipids. Therefore, we analysed 
sphingolipid composition of manipulated rat small intestine (mucosa and muscularis, 
respectively) at different time intervals: 0 h, 3 h, 6 h, 12 h and 24 h postsurgically. Recent 
studies on inflammation progressively revealed a key role of bioactive sphingolipids in 
inflammatory responses [Pettus et al., 2004b].  
3.1.1. The content of sphingolipids in rat small intestine samples at different 
time intervals after surgical manipulation 
 
3.1.1.1.  Analysis of sphingolipids by thin layer chromatography 
 
To determine the content of sphingolipids in rat small intestine before and after non-traumatic 
intestinal manipulation, mucosa and muscularis layers (50 mg and 25 mg wet weight, 
respectively) were collected at different time intervals (0 h, 3 h, 6 h, 12 h and 24 h) following 
surgery and subjected to lipid analysis. First, lipids were extracted with chloroform/methanol 
and analysed by thin layer chromatography (TLC) as described in section 2.2.3. Attention was 
initially focused on the content of ceramide, the primary sphingolipid found to play a role in 
inflammatory processes. Ceramide direct metabolic derivative, sphingomyelin (SM) was 
studied in parallel. To statistically analyse the content of sphingolipids in rat small intestine 
after surgical manipulation, three groups of samples were prepared and processed in 
independent experiments. For each sample, sphingolipid content was expressed as the 
percentage of total lipids extracted. Ceramide was detected in both rat intestinal mucosa and 
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muscularis, amounted about 4% of total lipids. The TLC data showed no significant change in 
the ceramide content in both layers and over the entire time range tested, when compared to 
non-manipulated controls (Fig. 9 A, B, C). As illustrated in Fig. 9 D, the content of its 
metabolic product, SM was found to slightly increase in muscularis versus mucosa (about 7% 
and 5%, respectively), with not statistically differences at any time interval postsurgery 
compared to control samples in both layers (Fig. 9 D). These studies provide evidence that 
intestinal manipulation do not induce changes in ceramide or SM composition of rat small 
intestine. 
 
 
 
 
 
 
 
 
 
 
 
 
   C                                                                      D                                                                       
 
 
 
 
 
 
 
 
 
 
Fig. 9 Effect of surgical manipulation on ceramide level in intestinal mucosa and muscularis.  The intestinal 
mucosa (A) and muscularis (B) were dissected as described in section 2.2.1.2, at indicated time intervals after 
manipulation. The specimens were homogenized in 600µl water and lipids were extracted with 
chloroform/methanol (1:2; v/v). After mild alkaline hydrolysis to remove glycerophospholipids, the lipid extracts 
were desalted and subjected to thin layer chromatography as described in sections 2.2.3.4, 2.2.3.6. In some 
experiments lipid extracts were subjected to anionic exchange chromatography. The TLC plate was run twice 
consecutively in chloroform/methanol/acetic acid (190:9:1; v/v/v). For detection of lipids TLC plate was sprayed 
with 8% phosphoric acid/10% cupric sulphate and developed for 10 min at 185°C. The mobility of standard 
lipids is indicated. C, D) Ceramide, SM (black columns, mucosa; grey columns, muscularis) were quantified by 
photodensitometry. Data are averages of three independent experiments. Cer, ceramide; FA, fatty acid; Chol, 
Cholesterol; SM, sphingolmyelin. 
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3.1.1.2. Analysis of sphingolipids by mass spectrometry  
 
High performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) is 
currently the only analytical procedure with appropriate structural specificity, sensitivity and 
quantitative precision used for simultaneously analysis of many different sphingolipids. The 
method can detect changes in sphingolipid levels as low as 1pmol or even less [Merrill et al., 
2005]. Note that these measurements were performed by Prof. A. Merrill at Georgia Insitute 
of Technology, Atlanta. To measure the content of sphingolipids in rat small intestine before 
and after manipulation (Fig. 10 A), mucosa and muscularis tissue samples, collected at 
different time intervals postsurgery (0 h, 3 h, 6 h, 12 h, and 24 h) were subjected to HPLC-
MS/MS. The results showed that at the indicated time intervals after manipulation and also at 
time zero, the amount (mol/mg wet weight) of all lipids analysed was higher in the muscularis 
layer than in mucosa (not shown). The most abundant sphingolipid was sphingomyelin with 
about 500 and 250 pmol/mg wet weight, followed by ceramide with almost 350 and 150 
pmol/mg wet weight in muscularis and mucosa, respectively. No significant change in the 
level of these two sphingolipids was detected at any time interval postsurgically in 
comparison with controls, non-manipulated rat intestine samples, in both, muscularis (Fig. 10 
B, C) and mucosa (not shown) thus confirming data obtained by TLC. HPLC-MS/MS also 
enabled us to accurately determine the levels of sphingoid bases and their phosphorylated 
counterparts. The amount of sphingosine was by one order of magnitude below the mass of 
ceramide, about 35 and 10 pmol/mg wet weight in muscularis and mucosa, respectively. Its 
content was statistically not different from controls at any post-traumatic interval tested in 
muscularis (Fig. 10 D) and mucosa, respectively. In both layers, the content of ceramide-1-
phosphate (C1P) and of sphingosine-1-phosphate (S1P) clustered within a picomolar range, 
no significant changes of any of these two sphingolipid-phosphates in the mucosa layer after 
intestinal manipulation being observed (data not shown). In contrast to the mucosa layer, the 
intestinal muscularis exhibited a time dependent increase in the content of C1P and S1P 
(Fig.10 E, F). As illustrated in Fig. 10 E, F the time courses of expression of the two 
sphingolipid-phosphates were quite similar. Both peaked at 6 h after intestinal manipulation 
reaching a more than 3-fold higher level at this time point when compared to non-manipulated 
rat intestinal samples (p < 0.01, n=3). After 6 h, the level of C1P decreased slowly but 
continuously towards control values, whereas that of S1P remained elevated to some extent at 
longer time intervals after surgery. Notably, the amount of both sphingolipids appears to be 
subjected to a long-time up-regulation post-surgery. 
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Hence, of the investigated sphingolipids only the content of C1P and S1P was increased, 
suggesting a possible role during the post-traumatic impairment of intestinal muscularis 
function. Moreover, these findings might indicate for the first time a direct involvement of 
these two bioactive lipids in the inflammatory responses within the intestinal muscularis, 
which has been suggested to play a major role in the pathogenesis of postoperative ileus 
[Kalff et al., 1998; Kalff et al., 1999b]. These results prompted us to focus our attention 
mainly on studies concerning muscularis layer rather than mucosa. 
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E                                                                            F 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10 Effects of intestinal manipulation (IM) on the sphingolipid content in intestinal muscularis externa 
(ME).  Rat small intestine was gently manipulated between two moist cotton applicators (A) and the 
muscularis layer was collected at the indicated time points after surgery. Sphingolipids were extracted and 
analysed by HPLC-MS/MS as described in section 2.2.4.  B, C, D) Data are average of triplicate determinations 
and are expressed as pmol of lipid/ mg wet weight in case of ceramide, sphingomyelin and sphingosine.  E, F) 
For C1P and S1P, data are means of triplicate measurements and expressed relative to control values obtained at 
t=0. Significantly different from control values (* p < 0.05, ** p<0.01). C1P, ceramide-1-phosphate; S1P, 
sphingosine-1-phosphate. 
 
3.1.2. Sphingolipid subspecies in rat small intestine samples at different 
time intervals after surgical manipulation 
 
  Usually tissues contain several sphingolipid subspecies, different in the degree of saturation 
and length of fatty acids as well as in their sphingoid base, which can be sphingosine or 
dihydrosphingosine. Since HPLC-MS/MS allows for analysis of such structural variations we 
studied subspecies composition of ceramide, sphingomyelin and C1P at different time 
intervals postsurgery. HPLC-MS/MS analysis revealed no significant changes in ceramide, 
sphingomyelin subspecies before and after trauma in muscularis samples (Fig. 11 A). As 
illustrated in Fig. 11 A and better in donut diagrams (Fig. 11 B), the most abundant 
subspecies of these two bioactive lipids in muscularis layer were C16 and C18 with about 
25% and 35%, followed by C24:1 and C20 with about 13 and 15%, and only 5-7% were C22 
and C24, respectively with no significant change over the entire time course. By contrast, 
some subspecies of C1P (C16, C18, C20 and C24:1 C1P) were significantly elevated after 
manipulation. This difference was evident early, peaked at 6h after manipulation and 
decreased slowly towards control levels.  Mass spectrometric analysis indicated that C16 and 
C18 were the prevailing C1P subspecies followed by C20 and C24:1 throughout the time 
course. Moreover, donut diagrams showed that muscularis layer after intestinal 
manipulation exhibited a larger fraction of the C16:0 fatty acid C1P subspecies versus C18:0 
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when compared to non-manipulated samples (Fig. 11 B). These results suggest that surgical 
manipulation induces changes not only in C1P content in rat intestinal muscularis tissue but 
obviously one certain subspecies was preferentially elevated namely C16 on the expense of 
C18. Although these changes are subtle, they demonstrate that manipulation of the small 
intestine alters both the total amount and the structure of C1P. Moreover, these data suggest 
that ceramide kinase uses preferentially C16 and C18 ceramides as substrates.  
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Fig. 11 Sphingolipid (ceramide, sphingomyelin, C1P) subspecies in the tunica muscularis externa (ME) 
after intestinal manipulation (IM).  A) Rat small intestine was gently manipulated and the muscularis layer 
was collected at the indicated time points after surgery. Sphingolipids were extracted and the indicated species 
including all detectable subspecies were determined by HPLC-MS/MS as described in section 2.2.4. Data from 
B represent donut diagrams showing a proportion of each indicated sphingolipid subspecies. Data are means of 
triplicate determinations and are expressed as pmol of lipid/mg wet weight. Numbers indicate chain length 
followed by the number of double bonds in the fatty acid.  0 h-control; C16DH, C16 dihydroceramide; Cer, 
ceramide; C1P, ceramide-1-phosphate; SM, sphingomyelin. 
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In conclusion, lipid analysis revealed that surgical manipulation of the small intestine had no 
effect on ceramide content, but induced an increase of two sphingolipid-phosphates, of S1P 
and of C1P contents, albeit only in muscularis layer. 
3.2. Studies with primary cultured rat intestinal smooth muscle cells 
 
The finding that gentle surgical manipulation of the small bowel resulted in an increase of 
S1P and C1P amounts only in the intestinal tunica muscularis externa, prompted us to analyse 
the potential involvement of these two sphingolipid-phosphates in inflammatory processes in 
primary cultured rat intestinal smooth muscle (RISM) cells. 
For this purpose, first a primary culture of rat intestinal smooth muscle cells was established. 
Second, we analysed the effects of S1P and C1P on various proinflammatory parameters, 
including, COX-2, PGE2, cytokines (IL-1ß, IL-6) and we tried to identify the sphingolipid 
downstream targets involved in the inflammatory cascade. Moreover, the potential role of 
sphingosine kinase (SK) as a mediator of an inflammatory response was determined. 
3.2.1. Characterization of rat intestinal smooth muscle (RISM) cells 
Smooth muscle cells represent the major cell type in the intestinal muscularis layer and their 
contractility is primarily affected after abdominal surgery [Kalff et al., 1999a]. We have 
therefore established a primary culture of RISM cells and examined the involvement of 
exogenous S1P and C1P in the potential proinflammatory response of these cells. Smooth 
muscle cells from the circular and the longitudinal muscle layer of rat small bowel were 
isolated by enzymatic digestion using type II collagenase and dispase II enzymes. The cells 
were cultured through 4-5 passages because at a higher passage of seven to eight the cells 
differentiate in myofibroblasts and fibroblasts. A homogeneous culture of smooth muscle 
cells was achieved by density gradient centrifugation. This enabled the separation from other 
cell types known to reside in the intestinal muscle layer, such as enteric neurons, macrophages 
and dendritic cells. To verify the smooth muscle origin and homogeneity of the cultures, we 
tested the expression of α-actin, a typical smooth muscle contractile protein. Expression of α-
actin was assessed by fluorescence microscopy and it was immunolocalized using an anti-
mouse smooth muscle α-actin monoclonal antibody as primary antibody. As shown in Fig. 12 
semi-confluent grown cells clearly exhibited immunoreactivity for smooth muscle α-actin, 
thus supporting the smooth muscle origin of our cell cultures. 
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Fig. 12 Expression of smooth muscle contractile protein, α-actin in primary cultured RISM cells. Cells 
plated on glass coverslips were grown to 50% confluence, fixed and stained with antibody against smooth 
muscle α-actin isoform (1:100). Anti-mouse secondary antibody conjugated to green fluorescent Alexa Flour 
488 dye was used at 1:200. Immunoreactivity was visualized by fluorescence microscopy (40x; A), (63x; B). 
 
3.2.2. Involvement of sphingosine-1-phosphate and ceramide-1-phosphate 
in inflammatory pathway in RISM cells 
 
Next, we addressed the possible role of S1P and C1P, the sphingolipid-phosphates whose 
levels changed after intestinal manipulation in inflammatory cascade using primary cultured 
RISM cells. 
3.2.2.1. Effects of sphingosine-1-phosphate on cyclooxygenase-2 expression 
and prostaglandin E2 formation in RISM cells 
 
It has been shown on the one hand that PGE2 formation via COX-2 is a causative mechanism 
of postoperative ileus [Schwarz et al., 2001]. On the other hand, S1P induced COX-2 
expression and PGE2 formation in different cell lines [Kim et al., 2003; Pettus et al., 2003b]. 
Therefore, in the present study we examined the expression of COX-2 protein in the presence 
of S1P in primary cultured RISM cells. The cells were treated for 4 h with different 
concentrations of S1P namely, 1 µM, 5 µM and 10 µM, respectively (Fig. 13 A) or with 10 
µM of S1P for different time intervals, 0, 30 min, 1 h, 4 h, 6 h and 16 h, respectively (Fig. 13 
B). Control cells were treated with the corresponding amount of methanol, the solvent used to 
solubilize S1P. At the respective time points, cells were harvested and lysed as described in 
section 2.2.7.1. The same amounts of protein (10 µg) were separated on acrylamide gels, and 
analysed by immunoblotting with anti-COX-2 primary antibody and protein G-HRP-
conjugated secondary antibody and detected by chemiluminescence.  
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As shown in Fig. 13 A, S1P induced a considerable increase of the 72-kDa COX-2 protein 
already at a concentration of 1 µM with no significant change in the induction at higher 
concentrations. The time course of S1P-induced COX-2 expression revealed a quite fast 
effect, reaching a maximum that in average amounted 400%± 60% already after 4 h (Fig. 13 
B). 
Considering that PGE2 has emerged as the prototypical eicosanoid with key function in acute 
inflammatory responses [Kuehl and Egan, 1980; Dempke et al., 2001], we also investigated 
the effect of S1P on PGE2 formation in primary cultured RISM cells.  Media were collected 
from cells treated for 4h with different S1P-concentration or alternatively cells were treated 
with 10 µM S1P for various time intervals and assayed for secreted PGE2 using an ELISA kit 
as described in section 2.2.8.1. 
As shown in Fig. 13 C, S1P clearly enhanced PGE2 formation in a concentration dependent 
manner ranging from 1 to 10 µM, with little further induction from 5 to 10 µM. Moreover, 
S1P induced a pronounced (about 6-fold) but transient increase in PGE2 formation after as 
early as 4 h (Fig. 13 D), returning to control levels at later time intervals. Note the similarity 
of the time course of the effect of S1P on COX-2 expression and on PGE2 production, 
respectively. Taken together, these results indicate that S1P induces COX-2 and PGE2 
production in primary cultured RISM cells. 
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Fig. 13 Effects of S1P on COX-2 induction and PGE2 synthesis in primary cultured RISM cells. A) Cells 
were incubated with the indicated concentration of S1P for 4 h or B) with 10 µM S1P for the indicated times. 
Control (time 0) cells were always treated accordingly in the presence of vehicle. Lysed cell protein (10 µg) was 
subjected to 10% SDS-PAGE and immunoblot analysis to determine COX-2 expression as described in section 
2.2.7.4. An anti-α-tubulin (α-tub) antibody was used to confirm equal loading. The blots shown are from one 
representative out of at least three independent experiments. C, D) Media from cells treated as mentioned above 
(in A and B) were collected and subjected to PGE2 analysis as described in section 2.2.8.1. Data are means ± 
S.D. from three independent experiments 
 
3.2.2.2.  Intracellular signalling pathway of sphingosine-1-phosphate-
induced cyclooxygenase-2 expression in RISM cells 
 
It is well known that S1P can act either as an extracellular ligand by binding to a family of G-
protein coupled receptors (GPCRs) or as an intracellular second messenger with so far 
unknown direct targets [Spiegel and Milstien, 2003]. All five members of the S1P-receptor 
family can be coupled to G i/o-proteins [Ishii et al., 2004]. Since the latter are inactivated by 
pertussis toxin (PTX) via ADP-ribosylation, this toxin was used to find out in a first approach 
whether the stimulatory effect of S1P on COX-2 expression is receptor-mediated. Thus, 
primary cultured RISM cells were preincubated with 100 ng/ml of PTX prior to stimulation 
with 10 µM S1P, shown previously to up-regulate COX-2. As illustrated in Fig. 14, pre-
treatment with PTX abrogates S1P-induced COX-2 expression. Furthermore, PTX-sensitivity 
indicates the involvement of a Gi-coupled S1P receptor in COX-2 expression. However, the 
considerable stimulation of COX-2 expression by PTX alone suggests the complexity of 
COX-2 expression. Of interest, S1P2 receptor was identified by RT-PCR in RISM cells (data 
not shown). 
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Fig. 14 Effects of PTX on S1P-induced COX-2 expression in primary cultured RISM cells. Cells were 
preincubated in the absence or presence of 100 ng/ml PTX for 2 h prior to treatment with 10 µM S1P for 4h. 
Controls (C) were treated accordingly using vehicle. Each sample (10 µg of protein) was subjected to 10% SDS-
PAGE, and the expression levels of COX-2 were determined by immunoblot analysis using anti-COX-2 
antibody. The blot shown is one representative out of at least three independent experiments. 
 
S1P receptor-mediated effects often imply MAPK signalling pathways, some of them being 
implicated in the regulation of COX-2 expression in different cell types [Kim et al., 2003; 
Damirin et al., 2005]. In this study, we therefore investigated whether S1P stimulates MAPKs 
using Western blot analysis with anti-phospho-specific antibodies against each enzyme. To 
confirm equal amount of protein loaded for each sample, blots were subsequently stripped and 
reprobed with an antibody against total ERK MAPK and total p38 MAPK, which are 
constitutively expressed in all cells at high levels. In cells treated with 10 µM S1P for 
different time intervals (15 min, 30 min, 1 h, 4 h and 16 h, respectively), the level of 
phosphorylated ERK was transiently increased, showing maximal activity within 30 min up 
to1 h of treatment (Fig. 15 A) and then decreased slowly at 4h after incubation with S1P. p38 
MAPK was also transiently activated by S1P treatment (Fig. 15 B). By contrast, JNK was 
insensitive to S1P administration (Fig. 15 C). These results indicate that S1P activates both, 
ERK MAPK and p38 MAPK, in primary cultured RISM cells.  
To determine a potential correlation of MAPK phosphorylation and S1P-induced COX-2 
expression, we used two pharmacological MAPK inhibitors. Cells were preincubated with 
PD-98059 a specific inhibitor for ERK MAPK [Dudley et al., 1995] or alternatively with SB 
239063 [Underwood et al., 2000] a p38 MAPK inhibitor, prior to administration of 10 µM 
S1P for 4 h. The same amounts of protein (10 µg) were separated on acrylamide gels, and 
analysed by immunoblotting with anti-COX-2 primary antibody and protein G-HRP-
conjugated secondary antibody followed by chemiluminescence. The preincubation of RISM 
cells with 5 µM of SB 239063, a specific p38 MAPK inhibitor, prior to S1P treatment 
completely inhibited COX-2 expression by S1P (Fig. 15 D). Similar results were obtained 
with 30 µM PD-98059, known to specifically inhibit ERK MAPK [Natzker et al., 2002] (Fig. 
15 D). These results indicate that both, ERK MAPK and p38 MAPK are essentially involved 
in S1P-induced COX-2 expression. 
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Fig. 15 Effect of MAPKs on COX-2 expression in primary cultured RISM cells. A, B, C) Cells were 
stimulated with 10 µM S1P for various time intervals. At the respective time points, the cells were harvested and 
lysed as described in section 2.2.7.1. Each sample (20 µg of protein) was subjected to 10% SDS-PAGE and 
phosphorylated ERK (pERK), phosphorylated p38 MAPK (pp38) or phosphorylated JNK (pJNK) were 
determined by immunoblotting with a specific antibody, respectively. Blots were stripped and reprobed with an 
antibody specific for total ERK, p38 MAPK or total JNK, respectively, to confirm equal loading.  D) Cells were 
pretreated with vehicle, 5 µM SB-239063 or 30 µM PD-98059 for 30 min prior to incubation with 10 µM S1P. 
After 4 h cells were lysed and 10 µg of protein was subjected to 10% SDS-PAGE and COX-2 expression level 
was determined by immunoblot analysis using anti-COX-2 antibody. An anti-α-tubulin (α-tub) antibody was 
used to confirm equal loading. The results shown are one representative out of at least three independent 
experiments (A-D). 
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3.2.2.3. Effects of sphingosine-1-phosphate on cytokine production in RISM 
cells 
 
It has been recently shown that intestinal surgical manipulation is accompanied by induction 
of the proinflammatory cytokine IL-6 within the tunica muscularis externa of rodent small 
intestine [Wehner et al., 2005]. Moreover, it was reported that S1P induces substantial IL-6 
secretion in human airway smooth muscle cells, thus indicating that S1P is an important 
inflammatory mediator implicated in the pathogenesis of asthma [Ammit et al., 2001]. 
To explore the potential role of S1P in inflammatory responses that accompany postoperative 
ileus, we examined the effects of exogenous S1P on cytokine expression in primary cultured 
RISM cells. Cells were treated with 5 and 10 µM of S1P, respectively, for 4 h (Fig. 16 A) or 
with 10 µM of S1P for different time intervals (1 h, 4 h and 6 h) (Fig. 16 B). Control cells 
were treated with the corresponding amount of methanol, the solvent used to solubilize S1P. 
At the respective time points, media were collected and subjected to ELISA assay to 
determine the concentration of IL-6 and IL-1ß, respectively. As shown in Fig. 16 A, S1P-
induced IL-6 production increased 4 h post-treatment with 5 and 10 µM S1P by (486,7 ± 40 
pg/ml) and (650 ± 23 pg/ml), respectively, compared to controls that amounted 260 ± 70 
pg/ml). The time course of IL-6 secretion by cells treated with 10 µM S1P revealed a 
maximal increase of IL-6 production at 4 h (200% ± 20%) (Fig. 16 B). S1P also induced an 
up-regulation of IL-6 at transcriptional level in a concentration-dependent manner. Maximal 
induction of transcription was obtained after 4 h treatment with 10 µM of S1P (Broere, 
personal communication). Moreover, S1P stimulated IL-6 secretion in a PTX-sensitive 
manner (not shown), suggesting that the effects of S1P on IL-6 expression are mediated via 
S1P receptors. In contrast to its observed effects on IL-6 secretion S1P did not induce 
expression of IL-1ß, neither on protein level (Fig. 16 C), nor on transcriptional level (data not 
shown). These results indicate that exogenous S1P can regulate the production of IL-6 in 
primary cultured RISM cells, suggesting one more time the possible implication of S1P in 
inflammatory processes that go along with postoperative ileus. 
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Fig. 16 Effects of S1P on cytokine secretion in primary cultured RISM cells. A) Cells were incubated with 
the indicated concentrations of S1P for 4 h or B) with 10 µM of S1P for the indicated times. Media from all 
samples were collected and IL-6 (A, B) or IL-1ß (C) was measured by ELISA assay as described in section 
2.2.8.2. Data are means ± S.D. of three independent experiments. * p < 0.05 significant different from controls. 
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3.2.2.3.1. Involvement of sphingosine kinase in TNF-α-induced IL-6 
cytokine production in RISM cells 
 
The finding that S1P induces production of the proinflammatory mediator IL-6 in primary 
cultured RISM cells, prompted us to investigate if sphingosine kinase (SK), which generates 
S1P, may function as an endogenous regulator of IL-6 secretion in response to TNF-α. 
Previous studies have shown that TNF-α induces a transient increase in S1P level in different 
cell lines [Pettus et al., 2003b]. Moreover, it was reported that SK1 activation is involved in 
the signal transduction pathway initiated by TNF-α in A549 cells [Billich et al., 2005]. 
Therefore, we explored whether or not SK is involved in IL-6 production in response to TNF-
α. Note that the latter is a pleiotropic cytokine whose secretion increases after intestinal 
manipulation of the rat small bowel (Speidel N, personal communication). 
To determine the potential role of SK as a mediator of TNF-induced IL-6 elevation, cells were 
stimulated for 4 h with TNF-α (10 ng/ml) in the absence or presence of 10 µM of N, N-
dimetylsphingosine (DMS) a potent inhibitor of SK (Endo K, 1991). IL-6 was determined as 
described in section 2.2.8.2 in the cell culture medium, after removal of detached cells by 
centrifugation using the respective ELISA. We observed that TNF-α induced an elevated IL-6 
secretion in primary cultured RISM cells (2-fold after 4 h treatment) (Fig. 17 A). As shown in 
Fig.17 A, DMS was capable to suppress production of IL-6 following stimulation of cells 
with TNF-α suggesting that SK activation is required for expression of IL-6. Furthermore, we 
measured the enzymatic activity of SK after treatment with TNF-α for 4 h. As becomes clear 
from Fig. 17 B, TNF-α induces an increase of SK enzyme activity by 191% ± 19%. Note also 
the generation of C1P indicating a simultaneous activation of ceramide kinase (CK) by TNF-
α (Fig.17 B, TLC). It can, however, not be excluded that in these cells SK does not exhibit 
substrate specificity, thus phosphorylating both, sphingosine and ceramide following TNF-α 
treatment. Taken together these results suggest that TNF-induced IL-6 secretion is dependent 
of SK and might also involve CK. 
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Fig. 17 Involvement of SK in TNF-induced IL-6 secretion in primary cultured RISM cells.  A) Cells were 
incubated with TNF-α (10 ng/ml) in the absence or presence of DMS (10 µM) for 4 h. Control cells (C) were 
always treated accordingly in the presence of vehicle. Media were collected and subjected to ELISA assay as 
described in section 2.2.8.2. Data are means ± S.D. from three independent experiments. *p < 0.05  treated with 
TNF vs. control cells B). Cells were incubated for 4h with vehicle (C) or with 10 ng/ml TNF-α. After 4 h, cells 
were harvested and sphingosine kinase activity was measured in cell homogenates using selective buffer 
conditions as described in section 2.2.5. 32P-labelled lipids were resolved by TLC with 1-butanol/methanol/acetic 
acid/water (80:20:10:20) and visualized by autoradiography using the bio-imaging analyzer Fujix bas 1000 
software, Tina 2.09. The radioactive spots corresponding to S1P and C1P were identified using S1P and C1P as 
standards. Data are means ± SD from two independent experiments, each with double determination. 
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3.2.2.4. Effects of ceramide-1-phosphate on cyclooxygenase-2 expression 
and prostaglandin E2 formation in RISM cells 
 
Although, ceramide-1-phosphate (C1P) was identified more than a decade ago, its potential 
biological functions have been reported only in the last few years [Liang et al., 2003; Pettus et 
al., 2003a]. In recent studies, C1P has emerged as a key regulator of inflammatory responses 
[Pettus et al., 2003a; Pettus et al., 2004a]. Our studies on rat small intestine indicated an 
increase in the amount of C1P in muscularis layer following surgical manipulation. Therefore, 
we addressed the potential involvement of this sphingolipid-phosphate in inflammatory 
processes in primary cultured RISM cells. 
First, we examined its effect on the expression of COX-2 protein using S1P as a positive 
control. The cells were treated with 10 µM of C1P and S1P, respectively. Control cells were 
treated with the corresponding amount of methanol, the solvent used to solubilize C1P and 
S1P. After 4 h, cells were harvested and lysed as described in section 2.2.7.1. The same 
amounts of protein (10 µg) were separated on acrylamide gels, analysed by immunoblotting 
with anti-COX-2 primary antibody and protein G-HRP-conjugated secondary antibody and 
detected by chemiluminescence. As shown in Fig. 18 A, C1P did not affect COX-2 
expression, whereas a considerable increase of the 72-kDa COX-2 protein has been observed 
in the presence of S1P (see also section 3.3.2.1.).  
We next analysed the effect of C1P on PGE2 formation in primary cultured RISM cells. 
Media from the cells used for COX-2 detection were collected and assayed for PGE2 secretion 
by ELISA. After 4 h, C1P induced a significant elevation of PGE2 production which was 
however, clearly below that obtained in the presence of S1P, at least at this time point (Fig. 18 
B). These results implicate the action of C1P in the pathway of PGE2 formation but at a 
different step than S1P. 
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Fig. 18 Effects of C1P on COX-2 expression and PGE2 formation in primary cultured RISM cells. A) Cells 
were incubated with 10 µM S1P and C1P, respectively for 4 h. Control cells (C) were always treated accordingly 
in the presence of vehicle. B) Media from samples mentioned above were collected and subjected to PGE2 
analysis as described in section 2.2.8.1. Data are means ± S.D. from three independent experiments. Lysed cell 
protein (10 µg) was subjected to 10% SDS-PAGE and immunoblot analysis to determine COX-2 expression as 
described in 2.2.7.4. An anti-α-tubulin (α-tub) antibody was used to confirm equal loading. The blots shown are 
from one representative out of at least three independent experiments. 
3.2.2.4.1. Effects of ceramide-1-phosphate on arachidonic acid release 
and prostaglandin E2 formation in RISM cells  
 
Since C1P clearly stimulated PGE2 production but had no effect on COX-2 expression, we 
investigated its effect on arachidonic acid release, which is indicative for an enhanced PLA2 
activity. PLA2 catalyses liberation of arachidonic acid from membrane phospholipids, which 
represents the initial and rate-limiting step in PGE2 synthesis [Pettus et al., 2004b]. 
For this purpose RISM cells were labelled overnight with [14C]-arachidonic acid and 
afterwards incubated with 10 µM of C1P for different time intervals (1 h, 4 h and 24 h, 
respectively). Control cells were treated with the corresponding amount of methanol, the 
solvent used to solubilize C1P. Following incubation, the medium was removed and an 
aliquot was submitted to scintillation counting to determine the amount of [14C] arachidonic 
acid released after treatment with C1P. As shown in Fig. 19 A, in the presence of C1P, the 
amount of arachidonic acid released from the cells increased in a time-dependent manner up 
to 3-fold at 24 h when compared to control cells. As determined by TLC, the data shown in 
Fig. 19 A refer only to arachidonic acid and not to arachidonic acid-labelled lipids. An aliquot 
of medium was used to determine the amount of PGE2 released in the presence of C1P at 
different time intervals. As obvious in Fig. 19 B, in the presence of C1P the synthesis of PGE2 
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ascended continuously up to 2.5-fold at 24 h. Taken together, these data indicate that C1P 
induces a time-dependent increase in both arachidonic acid and PGE2 release. 
 
            A 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
             B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19 Effects of C1P on arachidonic acid release and PGE2 formation in primary cultured RISM cells. A) 
Cells were labelled overnight with 0.2 µCi/ml [14C] arachidonic acid (AA) (3.7 µM). Then medium was removed 
and cells were rinsed three times with culture medium prior to incubation in the presence of vehicle (control, 
grey columns) or of 10 µM C1P (black columns) for the indicated times.  Results were normalized to cell protein 
levels. The results are presented as dpm of [14C] arachidonic acid/ml medium. In addition, media were subjected 
to reversed phase chromatography as described above (see section 2.2.3.4). The samples were applied on 
Silicagel-60 TLC-plates developed with n-hexane/diethyl ether/glacial acetic acid (70:30:1, by volume). 
Arachidonic acid was visualized by autoradiography using the bio-imaging analyzer Fujix bas 1000 software, 
Tina 2.09. B) In parallel experiments, the synthesis of PGE2 was assayed as described in section 2.2.8.1. Data are 
means ± S.D. of three independent experiments. C, controls. 
 
To examine whether the effect of C1P on arachidonic acid release was specific, RISM cells 
were treated with closely related lipids such as, didecanoylphosphatidic acid (PA), ceramide 
(Cer) and also with C1P for 4 h and 24 h, respectively. Only C1P induced significant 
arachidonic acid release (Fig. 20) when compared with control cells. Thus, the effect of C1P 
on arachidonic acid release in RISM cells is highly specific. 
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Fig. 20 Effects of C1P-related lipids on arachidonic acid release in primary cultured RISM cells. Cells 
were labelled overnight with 0,2 µCi/ml [14C] arachidonic acid (AA) (3,7 µM). Subsequently, medium was 
removed and the cells were rinsed three times with culture medium prior to incubation in the presence of vehicle 
(control, C) or of 10 µM of C1P, didecanoylphosphatidic acid (PA), ceramide (Cer), for 4 h (grey columns) or 
24 h (black columns). Results were normalized to cell protein levels. The results are presented as dpm of [14C] 
arachidonic acid/ml medium. Data are means ± S.D. of three independent experiments. 
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3.3. Activity of sphingosine kinase after mechanical stress of RISM cells  
 
The data obtained with primary cultured RISM cells suggest that S1P and C1P have 
proinflammatory effects in these cells. Moreover, they support the hypothesis that 
sphingolipids might be involved in inflammatory responses occurring in the muscularis layer 
after surgical manipulation of the small intestine. To find out whether mechanical stress 
supposed to be causative for the inflammatory processes of intestinal muscularis is correlated 
with increased levels of S1P and C1P, cells were subjected to a mechanical stretch to mimic 
the insult that has been reported to induce postoperative ileus. Cells were seeded into 
collagen-coated silicone elastomer-base culture plates and subjected to stretching as described 
in section 2.2.2.6. At 30 min and 4 h post-stretching, cells were harvested and the enzymatic 
activity of sphingosine kinase (SK) was measured. As shown in Fig. 21, an induction of SK 
activity occurred already at 30 min postmechanical stretch as assessed by the quantification of 
its product, S1P. Interestingly, the content of C1P was also enhanced after mechanical stretch 
(Fig. 21, TLC) suggesting activation of ceramide kinase in response to manipulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21 Effect of mechanical stretch on SK activity in RISM cells. Cells were serum-deprived for 24h and 
then exposed to mechanical stretch for 2 x 30 min with 5 min break in between. At the indicated time intervals 
after stretching, cells were harvested and sphingosine kinase activity was measured in cell homogenates using 
selective buffer conditions as described in section 2.2.5. 32P- labelled lipids were resolved by TLC with 1-
butanol/methanol/acetic acid/water (80:20:10:20) and visualized by autoradiography using the bio-imaging 
analyzer Fujix bas 1000 software, Tina 2.09. The radioactive spots corresponding to authentic S1P and C1P were 
identified using S1P and C1P as standards. The chromatogram shown is one representative out of three 
independent experiments. 
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3.4.  In vivo induced endotoxemia  
 
Previous studies have shown that systemically administrated living bacteria or endotoxin have 
a detrimental effect on metabolic and barrier functions of the small intestine and thus 
promotes the translocation of bacteria from the gut lumen to the portal or systemic circulation 
[Swank and Deitch, 1996]. It has been shown that a single, sublethal dose of bacterial 
lipopolysaccaride (LPS) disrupts in vivo and in vitro gastrointestinal motility and transit 
[Weisbrodt et al., 1996; Eskandari et al., 1997; Cullen et al., 1999b]. Moreover, it has been 
demonstarted that LPS causes ileus by initiating an inflammatory response within the 
intestinal muscularis layer [Eskandari et al., 1997] with an excess production of inflammatory 
mediators [Turler et al., 2002].  
To analyse the potential involvement of sphingolipids in LPS-induced ileus, we used an in 
vivo standard rodent model of endotoxemia. Endotoxemia was induced by a single 
intraperitoneal injection of LPS (10 mg/kg). As a result of LPS administration, the levels of 
sphingolipids in intestinal tissue might be altered. We therefore analysed the sphingolipid 
composition of the rat small intestinal tissue (mucosa and muscularis layers, respectively) at 
different time intervals i.e. 0 h, 3 h, 6 h, 12 h and 24 h after LPS exposure. Several studies are 
suggesting a role of bioactive sphingolipids in LPS signalling [Haimovitz-Friedman et al., 
1997; Memon et al., 1999; Wu et al., 2004]. 
3.4.1. The content of sphingolipids in rat small intestine samples at different 
time intervals after lipopolysaccaride administration 
3.4.1.1. Analysis of sphingolipids by thin layer chromatography 
 
To analyse the effect of LPS on sphingolipid composition in rat small intestine, mucosa and 
muscularis layers (50 mg and 25 mg wet weight, respectively) were collected at various time 
intervals (0 h, 3 h, 6 h, 12 h and 24 h) following LPS injection (10 mg/kg) and subjected to 
lipid analysis. Lipids were extracted and analysed by TLC as described in 2.2.3. Much 
attention was focused on ceramide level, the primary sphingolipid found to play a role in 
inflammatory processes. To statistically analyse the level of sphingolipids in rat small 
intestine after LPS injection, three groups of samples were prepared and processed in 
independent experiments. For each sample, ceramide content was expressed as the percentage 
of total lipids extracted. Ceramide was detected in both, rat intestinal mucosa (Fig. 22 A) and 
muscularis (Fig. 22 B) layers, amounted about 4% and 3%, respectively of total lipids. The 
results showed no significant change neither in the level of ceramide (Fig. 22 C) nor of other 
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sphingolipids (not shown) at any time point after LPS injection when compared with 0 h, i.e. 
non-treated controls in both layers.  
 
                      A                                    B       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       C 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22 Effect of LPS treatment on ceramide content in intestinal mucosa (MC) and muscularis (ME).  Rat 
intestinal mucosa (A) and muscularis (B) were collected at indicated time points after LPS administration. The 
specimens were homogenized in 600 µl water and lipids were extracted with chloroform/methanol (1:2,v/v). 
After mild alkaline hydrolysis to remove glycerophospholipids, lipid extracts were desalted and subjected to 
TLC as described in sections 2.2.3.4, 2.2.3.6. In some experiments lipid extracts were subjected to anionic 
exchange chromatography. The TLC plate was run twice consecutively in chloroform/ methanol/acetic acid 
(190:9:1; v/v/v). For detection of lipids the TLC was sprayed with 8% phosphoric acid/ 10% cupric sulphate and 
developed for 10 min at 185°C. The mobility of standard lipids is indicated. C) Ceramide (black columns, 
mucosa; grey columns, muscularis) was quantified by photodensitometry. Data are averages of three 
independent experiments. Cer, ceramide; FA, fatty acid; Chol, Cholesterol. 
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3.4.1.2. Analysis of sphingolipids by mass spectrometry 
 
To confirm the results obtained by TLC analysis and to detect sphingolipids, which are 
normally found in very low amounts in biological materials we employed high performance 
liquid chromatography tandem mass spectrometry (HPLC-MS/MS). 50 mg wet weight of 
mucosa layer and 30 mg wet weight of muscularis layer from control and LPS-treated animals 
(0 h, 3 h, 6 h, 12 h and 24 h) respectively, were subjected to lipid analysis by HPLC-MS/MS. 
No significant change in the amount of ceramide, sphingomyelin and sphingosine was 
detected at any time interval after LPS injection in comparison with controls, non-treated rat 
intestine samples, in both, mucosa and muscularis layers. In contrast, the amounts of C1P and 
S1P were significantly affected by LPS treatment, intestinal muscularis exhibiting a time 
dependent increase in the content of C1P and S1P (Fig. 23 A, B). C1P and S1P ranged in a 
picomolar region, no significant changes of any of these two sphingolipid-phosphates being 
observed in the mucosa layer after LPS injection (data not shown). The content profiles of the 
two sphingolipid-phosphates were quite similar. Both peaked at 12 h after injection, reaching 
a more than 3-fold higher level at this time point when compared with non-treated rat 
intestinal samples. After 12 h the level of both, decreased towards control levels (Fig. 23 A, 
B). Note that a significant increase in S1P content occurred even at 6 h post-treatment.  
These results indicate that C1P and S1P are the only sphingolipids of the investigated ones 
that could play a role in sepsis-induced ileus. The findings that intestinal manipulation 
induced likewise an increase in the contents of C1P and S1P support the hypothesis that both, 
LPS- and postoperative induced-ileus share a number of similar pathways [Eskandari et al., 
1997; Kalff et al., 1998]. Moreover, these findings might indicate for the first time a direct 
involvement of these two bioactive sphingolipids in LPS signalling in an animal model. 
We have also examined the effects of LPS on sphingolipid (ceramide, sphingomyelin, C1P) 
subspecies measured by HPLC-MS/MS. HPLC-MS/MS analysis revealed similar results 
obtained after intestinal manipulation with no significant changes in ceramide, sphingomyelin 
subspecies before and after LPS administration. Likewise, the most abundant subspecies of 
these two bioactive lipids in muscularis layer over the entire time course were C16 and C18 
followed by C24:1 and C20 and C22 and C24, respectively with no significant change at any 
time point post-treatment. By contrast, some subspecies of C1P (C16, C18, C20 and C24-
C1P) were significantly elevated after LPS injection. This difference was evident early, 
peaked at 12 h after LPS administration and then decreased slowly towards control values.  
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Fig. 23 Effects of LPS on C1P and S1P content in rat intestinal muscularis (ME). Rats were injected 
intraperitoneally with LPS (10 mg/kg) and sacrificed at various time points (0h, 3 h, 6h, 12 h and 24 h) after 
treatment. Muscularis was harvested as described in section 2.2.1.3 at indicated time points after LPS 
administration. Sphingolipids were extracted from muscularis layer and analysed by HPLC-MS/MS as described 
in section 2.2.4. A, B) Data are averages of triplicate measurements and expressed relative to control values 
obtained at t=0. Significantly different from control values (* p < 0.05, ** p<0.01). 
 
3.4.2. Involvement of sphingosine kinase in LPS induced IL-6 cytokine 
production in RISM cells 
 
Our findings that intraperitoneal injection of LPS to rodents results in an increase of S1P and 
C1P levels only in the intestinal tunica muscularis externa, prompted us to analyse the 
potential involvement of these two sphingolipid-phosphates in LPS-induced inflammatory 
responses in primary cultured RISM cells. A recent study showed that sphingosine kinase 
(SK) is activated by LPS and mediates LPS-induced cell survival in macrophages [Wu et al., 
2004]. However, studies that address whether or not SK is involved in LPS-mediated 
production of cytokines are not available.  
We have therefore examined the effect of LPS on IL-6 production in primary cultured RISM 
cells. The cells were treated for 4 h with 0.1 and 1 µg/ml LPS, respectively. Control cells 
were treated with the corresponding amount of vehicle. At the respective time point, the 
media were collected and subjected to ELISA assay to determine the concentration of IL-6 
released in the medium. As shown in Fig. 24 A, S1P-induced IL-6 production in RISM cells 
increased significantly upon 1 µg/ml LPS treatment (262% ± 45 %). To determine the 
necessity of SK as a mediator of LPS-induced IL-6 elevation, cells were treated for 4 h with 
LPS (1 µg/ml) in the absence or presence of 10 µM N, N-dimetylsphingosine (DMS), a potent 
inhibitor of SK. IL-6 content was determined in the culture media as described in 2.2.8.2. We 
observed that LPS induced-IL-6 secretion in primary cultured RISM cells was suppressed by 
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DMS, suggesting that SK activation is required for expression of IL-6 (Fig. 24 A). In addition 
we measured the enzymatic activity of SK after treatment with LPS for 4 h. As shown in Fig. 
24 B, LPS induced a clear increase of SK activity by about 230% ± 18%. Note the generation 
of C1P suggesting the possible activation of ceramide kinase (CK) by LPS (Fig. 24 B). It can, 
however, not be excluded that in these cells SK does not exhibit substrate specificity, thus 
phosphorylating both, sphingosine and ceramide following LPS treatment. Taken together 
these results suggest that LPS-induced IL-6 secretion is dependent of SK and might also 
involve CK. 
     A 
 
 
         
 
 
 
 
 
 
 
 
 
 
     B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24 Involvement of SK in LPS-induced IL-6 secretion in primary cultured RISM cells.  A) Cells were 
incubated with the indicated concentrations of LPS in the absence or presence of DMS (10 µM). Control cells 
(C) were always treated accordingly in the presence of vehicle. After 4 h media were collected and subject to 
ELISA assay as described in section 2.2.8.2. Data are means ± S.D. from three independent experiments. *p < 
0.05  treated with 1 µg/ml LPS vs. control cells. B). Cells were incubated for 4 h with vehicle (C) or with 1 
µg/ml LPS. After 4 h cells were harvested and SK activity was measured in cell homogenates using selective 
buffer conditions as described in section 2.2.5. 32P-labelled lipids were resolved by TLC using 1-
butanol/methanol/acetic acid/water (80:20:10:20) as sovent system and visualized by autoradiography using the 
bio-imaging analyzer Fujix bas 1000 software, Tina 2.09.  The radioactive spots corresponding to S1P and C1P 
were identified using S1P and C1P as standards. Data are means ± SD from two independent experiments, each 
with double determinations. 
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4. Discussion 
 
Gentle manipulation of the small intestine as well as LPS cause ileus by initiating an 
inflammatory cascade within the intestinal smooth muscle layer accompanied by decrease in 
smooth muscle contractility. Various mediators have been found to be involved in the 
inflammatory cascade. Since sphingolipids are emerging as a novel class of bioactive lipids in 
the regulation of inflammation, in this study we tried to find out whether sphingolipids could 
contribute to the onset of inflammatory responses induced by surgical manipulation of the 
small intestine or by endotoxemia. 
4.1. Surgical manipulation of the bowel increases the contents of 
sphingosine-1-phosphate and ceramide-1-phosphate in the intestinal 
muscularis  
 
To investigate the potential role of sphingolipids in postoperative ileus, we used an in vivo 
standardized surgical rodent model of intestinal manipulation.  For an accurate analysis we 
did not use the entire small bowel but the selectively isolated muscularis and mucosa layers. 
Since ceramide was the primary sphingolipid found to play a role in inflammatory responses 
we started by analysing its content in intestinal mucosa and muscularis after surgical 
manipulation. Data obtained by TLC showed no significant changes in the content of 
ceramide at any time point after surgical manipulation versus control. Additionally, we did 
not find any difference in the amount of ceramide derivatives such as SM or sphingosine in 
both layers. Currently, technologies used for lipid analyses include besides chromatography 
like TLC [Touchstone, 1995; van Echten-Deckert, 2000], nuclear magnetic resonance (NMR) 
and mass spectrometry (MS). Although, NMR can be used to measure simultaneously all 
kinds of small molecule metabolites, it has the major disadvantage that it is relatively 
insensitive complared to MS-based technique. MS is both sensitive and can be very specific 
[van Echten-Deckert and Herget, 2006]. MS is used to identify and quantify metabolites after 
separation by gas chromatography (GC), high performance liquid chromatography (HPLC) 
[Muthing, 2000; Sullards and Merrill, 2001] or capillary electrophoresis. GC-MS offers high 
chromatographic resolution, but requires chemical derivatization for many biomolecules and 
only volatile chemicals can be analysed without derivatization. Therefore some large and 
polar metabolites cannot be analysed by GC. Instead, HPLC has lower chromatographic 
resolution but it has the advantage that a much wider range of lipids can be measured. For a 
precise quantification of sphingolipid content postsurgically, we employed HPLC-MS/MS 
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that also enabled determination of sphingolipids present in very low amounts in tissues. 
HPLC-MS/MS showed that the spingolipid profiles in mucosa and muscularis are not 
identical. This is not surprising since they consist of different cell types and the inflammation 
mainly occurs in the musuclaris layer. Whereas no significant changes of any of the 
sphingolipids analysed have been observed in the mucosa layer after intestinal manipulation, 
the muscularis exhibited a time dependent increase in the content of C1P and S1P. This is a 
remarkable finding indicating for the first time an implication of these two bioactive lipids in 
an inflammatory response in a pathological situation [Dragusin et al., 2006]. Moreover, these 
results show a direct correlation of the content of these bioactive sphingolipids in the 
intestinal muscularis and the inflammatory processes observed in this tissue layer postsurgery. 
We assume that surgical manipulation leads to an increase in the content of S1P and C1P by 
inducing the expression of sphingosine kinase (SK) and ceramide kinase (CK), respectively. 
SK, the enzyme that generates S1P, was localized in murine Peyers patches [Baumruker et 
al., 2005], the lymphatic nodules that are found predominantly in ileum. Note that we indeed 
detected a significant increase in the activity of SK and also of CK after mechanical 
manipulation of primary cultured RISM cells. However, we cannot exclude that, cells other 
than RISM cells that occur in the muscularis layer contribute to an augmentation of S1P and 
C1P content. It can also be speculated that the increase in S1P derives from platelets. S1P is 
abundantly stored in platelets and released extracellularly upon stimulation [Yatomi et al., 
1995; Yatomi et al., 1997]. Therefore, an increased level of S1P might occur under conditions 
in which the integrity of the vascular endothelial cells is disturbed. Note that, vascular 
endothelium is normally injured after trauma and shock [Lichtman, 2001]. 
Usually, tissues contain several sphingolipid subspecies, which differ in the degree of 
saturation and length of fatty acids as well as in their sphingoid base. The muscularis layer 
after intestinal manipulation exhibited a larger fraction of the C16:0 fatty acid C1P subspecies 
versus C18:0 when compared to non-manipulated samples. By contrast, C18 ceramide was 
found to be the prevailing subspecies in the intestinal muscularis. Furthermore, ceramide 
kinase was recently characterized regarding its substrate specificity in HEK293 cells and the 
enzyme demonstrated no preference for ceramides with saturated (C16, C18) versus 
unsaturated (C24:1) acyl chain lengths [Sugiura et al., 2002]. Thus, the finding that C16-C1P 
was the major subspecies of C1P found in muscularis after surgical manipulation could not be 
explained by substrate preference but rather by subcellular availability of the substrate. In this 
context, it was demonstrated that the ceramide transport protein (CERT) preferentially 
transported C16 ceramide from the ER to the trans-Golgi network where CK is localized 
  DISCUSSION 
 76
[Hanada et al., 2003; Kumagai et al., 2005]. We therefore, suggest that intestinal manipulation 
could affect the transport of C16 ceramide in RISM cells. Although the changes in C1P 
subspecies are subtle, they demonstrate that manipulation of the small intestine alters both the 
total amount and the structure of C1P. 
4.1.1. Putative implication of sphingosine-1-phosphate and ceramide-1-
phosphate in inflammatory responses initiated by surgical 
manipulation 
  
It has been reported that surgical manipulation also increases the number of mast cells and 
induces their activation [Kalff et al., 1998]. Once activated, these cells degranulate and release 
potent inflammatory mediators such as histamine, TNF-α, proteases and produce newly 
synthesized mediators including prostaglandins and a variety of cytokines [Galli et al., 1991; 
Wershil, 1995]. Moreover, mast cells activation can amplify the recruitment of leukocytes 
through the release of histamine and the up-regulation of adhesion molecules [Kubes and 
Kanwar, 1994; Wershil et al., 1996]. A massive and persistent extravasation of leukocytes 
into the intestinal muscularis also occurs after surgical manipulation due to release of 
proinflammatory cytokines by the dense network of resident muscularis macrophages. Many 
studies pointed to a role of sphingolipids in mediating priming and activation of various cells 
of the immune system [El Alwani et al., 2006]. One could hypotesize that S1P and C1P 
participate in inflammatory processes that accompany postoperative ileus by inducing mast 
cell degranulation and/or leucocyte extravasation. For instance, it was found that increased 
S1P levels lead to activation of mast cells and the release of inflammatory mediators such as 
leukotrienes and cytokines [Prieschl et al., 1999]. Furthermore, it was observed that cross-
linking of a high-affinity receptor for IgE (FcεRI) in mast cells activates SK1 leading to 
generation and secretion of S1P. This in turn activates its receptors, S1P1 and S1P2 that are 
required for mast cell degranulation and chemotaxis [Jolly et al., 2002]. S1P activates its 
receptors on the same and /or neighboring cells in an autocrine or paracrine manner. Up to 
now, it was a mystery how S1P produced inside cells could reach its receptors on the cell 
surface. Membrane lipids do not spontaneously exchange across lipid bilayers since the polar 
head groups do not easily transverse the hydrophobic interior of the membrane. Therefore, 
cells have many special transport proteins for this purpose. In a very recent study it was 
shown that S1P is transported out of rodent and human mast cells by ABCC1, an ATP-
binding cassette (ATP) transporter [Mitra et al., 2006]. Additionally, it was reported that mice 
deficient in ABCC1 display impaired imflammatory responses due to decreased secretion of 
leukotriene, LTC4 [Wijnholds et al., 1997]. One could speculate that the impaired 
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inflammatory responses might be partly caused by decreased secretion of S1P that acts not 
only in an autocrine manner to regulate mast cells functions [Olivera and Rivera, 2005] but 
also it activates other cells involved in inflammatory responses [Graeler and Goetzl, 2002; 
Jolly et al., 2002; Roviezzo et al., 2004]. CK and its product, C1P were also proposed to 
function in degranulation of mast cells [Mitsutake et al., 2004]. In addition, cell migration is 
also an important event in inflammatory processes, which is facilitated by the expression of 
adhesion proteins on endothelial cells. It was found that S1P acts as an effective regulator of 
migration of freshly isolated human neutrophils across endothelial cells [Kawa et al., 1997; 
MacKinnon et al., 2002]. In addition, it was shown that expression of adhesion molecules on 
endothelial cells in response to TNF-α is mediated by SK activation and S1P generation [Xia 
et al., 1998]. Likewise, S1P is a potent chemotactic factor for lymphocytes. It stimulates 
migration and enhances survival of splenic T cells, these actions being dependent on the 
differential expression of S1P receptors and S1P concentration in blood [Graeler and Goetzl, 
2002; Rosen and Goetzl, 2005]. Moreover, S1P and C1P favour survival of macrophages by 
preventing ceramide accumulation, thus blocking apoptosis [Gomez-Munoz et al., 2003; 
Gomez-Munoz et al., 2005]. By contrast, ceramide and sphingosine are well known inducers 
of programmed cell death in mast cells [Itakura et al., 2002]. 
4.2. Sphingosine-1-phosphate and ceramide-1-phosphate induce 
inflammatory responses in RISM cells 
 
It was shown before that intestinal manipulation induces COX-2 expression, which results in 
increased synthesis of prostaglandins within the muscularis [Schwarz et al., 2001]. Up-
regulation of COX-2 could be attributed to resident macrophages but a contribution of smooth 
muscle cells or other cellular populations that inhabit the intestinal muscularis externa cannot 
be ruled out. Regardless of the complexity of the inflammatory response within the intestinal 
muscularis, probably involving several cell types, our study focused on elucidating the 
involvement of sphingolipids in inflammatory reactions using primary cultured RISM cells. 
The latter represent not only the prevailing cell type in the intestinal muscularis layer but have 
been shown to be mostly affected in their function, as suggested by well documented post-
operative dysmotility [Kalff et al., 1998; Kalff et al., 1999b]. 
Up to now, most of the research concerning the involvement of sphingolipids in inflammatory 
processes focused on diverse cell lines, whereas less work addressed their role in primary 
cultured cells. First, we determined whether ceramide as precursor of S1P and C1P or neutral 
SMase that generates endogenous ceramide induced COX-2 expression in RISM cells. We 
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found that ceramide and SMase do not induce a significant increase in COX-2 protein 
expression in these cells. These results together with the finding that intestinal manipulation 
does not change the content of ceramide in intestinal muscularis exclude the possible 
involvement of ceramide in inflammatory processes that accompany postoperative ileus. 
Initial reports regarding a role of sphingolipids in inflammation showed that sphingosine and 
a cell-permeable ceramide (C2-ceramide) enhanced IL-1-mediated PGE2 formation by COX 
activation in human fibroblasts [Ballou et al., 1990; Ballou et al., 1992]. Furthermore, 
treatment of human mammary epithelial cells with ceramide or SMase was shown to enhance 
COX-2 expression and PGE2 formation [Subbaramaiah et al., 1998]. However, the hypothesis 
that ceramide is involved in COX-2 induction does not reconcile easily with the proposed role 
of ceramide in inducing cell death and the proinflammatory nature of COX-2 in cancer [Pettus 
et al., 2004b]. On the other hand, ceramide was shown to inhibit COX-2 induction in response 
to LPS by inhibition of NF-kB and AP-1 [Hsu et al., 2001].  
Therefore, we investigated the potential involvement of S1P and C1P in inflammatory 
processes in RISM cells, the sphingolipis-phosphates whose levels specifically increased in 
the muscularis layer after intestinal manipulation. 
4.2.1. Sphingosine-1-phosphate stimulates cyclooxygenase-2 induction and 
PGE2 production in RISM cells 
 
There is experimental evidence for the involvement of S1P in COX-2 regulation. Our data 
suggest that exogenous S1P is sufficent to induce COX-2 and PGE2 production in a time and 
concentration dependent manner in primary cultured RISM cells [Dragusin et al., 2006]. Our 
results are consistent with findings of others, closely correlating S1P with the metabolism of 
eicosanoids [Pettus et al., 2005]. It was therefore not surprising that S1P modulates PGE2 
synthesis. But it was of some surprise that modulation of PGE2 synthesis by S1P, previously 
described primarily in diverse cell lines [Pettus et al., 2003b; Chalfant and Spiegel, 2005] is 
also valid in primary cultured RISM cells. In a recent study, the effects of ceramide, 
sphingosine and S1P on COX-2 induction were compared under identical conditions and the 
results showed that the actions of S1P were the most potent. In addition, the actions of 
ceramide and sphingosine were prevented when SK1 activity was knocked down via RNAi, 
thus demonstrating that the actions of these two sphingolipid metabolites require metabolic 
conversion to S1P [Pettus et al., 2003b]. Moreover, RNAi directed against S1P lyase and S1P 
phosphatase, which should increase S1P levels, augmented COX-2 activation and 
consequently PGE2 generation. A critical role of SK1 in mediating PGE2 production was also 
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observed in A 549 cells [Billich et al., 2005]. A recent study suggested moreover that SK1 
expression is upregulated in rat colon tumors implying an involvement of SK1/S1P pathway 
in the regulation of the COX-2/PGE2 pathway in colon cancer cells [Kawamori et al., 2005]. 
Taken together, these data define a role of S1P in COX-2 induction and PGE2 production. 
4.2.2.  Sphingosine-1-phosphate-induced cyclooxygenase-2 expression is 
pertussis toxin sensitive and mediated by MAPKs in RISM cells 
 
It is well known that S1P can act either as an extracellular ligand by binding to a family of G-
protein coupled receptors (GPCRs) or as an intracellular second messenger with so far 
unknown direct targets [Spiegel and Milstien, 2003]. All five members of the S1P-receptor 
family can be coupled to G i/o-proteins [Ishii et al., 2004]. Since the latter are inactivated by 
pertussis toxin (PTX) via ADP-ribosylation, we used this toxin to find out in a first approach 
whether the stimulatory effect of S1P on COX-2 expression is receptor-mediated. Previous 
studies on human airway smooth muscle cells showed that modulation of cytokines by S1P 
was PTX independent indicating that it did not involve G-protein coupled receptors. By 
contrast, in RISM cells the PTX-sensitivity of S1P induced COX-2 expression implicates the 
involvement of Gi/o coupled S1P-receptors. Interestingly it was found that S1P2 plays a key 
role in myogenic differentiation [Donati et al., 2005]. Based on several previous studies [Ishii 
et al., 2004] we assume that S1P2 also mediates S1P-induced COX-2 expression in RISM 
cells. Note that Broere R. from our group identified the presence of S1P2 in RISM cells by 
RT-PCR. 
S1P-receptor-mediated effects often imply MAPK signalling pathways. ERK MAPK pathway 
usually promotes cell proliferation whereas activation of SAPK/JNK is important in 
controlling apoptosis and p38 MAPKs appear to be key regulators of inflammatory response 
in immune cells [Johnson and Lapadat, 2002].  Due to its tumor-promoting function, 
inflammation is often considered a proliferative rather than an apoptotic process [Chalfant and 
Spiegel, 2005]. Thus, one would imply activation of the ERK and/or p38-signalling pathway 
upstream of COX-2 expression. In primary cultured RISM cells, S1P-induced COX-2 
expression appears to involve phosphorylation of both, ERK and p38 MAPK signalling 
pathways. This was proved by using two different specific inhibitors, PD-98059 and SB 
239063, for ERK and for p38 MAPK inhibitors, respectively. In human amnion-derived 
WISH cells [Kim et al., 2003] and also in human coronary artery smooth muscle cells 
[Damirin et al., 2005], S1P-modulated COX-2 expression occurs only by activation of ERK 
signalling pathway. Remarkably, our results are similar with those obtained for the pro-
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myogenic and anti-proliferative S1P2-mediated action of S1P in myoblasts [Donati et al., 
2005]. Thus, it appears that S1P induces two rather opposite physiological processes, namely 
morphogenesis and inflammation, albeit in undifferentiated myoblasts and differentiated 
smooth muscle cells, respectively, using similar signalling pathways. This finding once more 
emphasises that similar signalling pathways can induce different cellular responses depending 
on the developmental stage of a cell.  
4.2.3. Sphingolipid kinases mediate IL-6 cytokine production in response to 
TNF-α in RISM cells 
 
IL-6 is a prototypical inflammatory cytokine whose expression was induced in the muscularis 
layer through the intestinal manipulation procedure [Wehner et al., 2005].  
In the present study, the effect of S1P on cytokine production was also addressed. Our data 
suggest that exogenous S1P induces a time and concentration dependent increase of IL-6 
secretion in a PTX-sensitive manner. Interestingly, in human airway smooth muscle cells IL-6 
secretion by S1P was PTX-insensitive [Ammit et al., 2001] reflecting either activation of 
(non-Gi-coupled) receptors or intracellular actions of internalized S1P. Moreover, the direct 
measurement of IL-6 release after manipulation indicated that extravasated leukocytes are 
major producers of IL-6 [Wehner et al., 2005]. However, previous studies showed that 
intestinal smooth muscle cells have the capacity to produce IL-6 in response to Il-1ß or TNF-
α [Khan et al., 1995; Ng et al., 2003]. In the present study, we found that the induction of IL-6 
secretion by TNF-α was suppressed by a specific SK inhibitor, dimethylsphingosine (DMS), a 
pharmacological inhibitor of both SK1 and SK2 suggesting that TNF-α acts through induction 
of SK in RISM cells. Indeed, we found an increase in SK activity upon stimulation of RISM 
cells with TNF-α. Interestingly, in TNF-α stimulated RISM cells we also observed the 
generation of C1P indicating that either in these cells SK does not exhibit substrate specificity 
thus phosphorylating both, sphingosine and ceramide or that a simultaneous activation of CK 
occurs. Since ceramide content is quite elevated in these cells, it appears more likely that the 
activity of CK was monitored simultaneously. The involvement of SK in TNF-α induced 
cytokine production was also reported in A549 carcinoma cells. Studies with RNAi against 
SK1 and SK2 reported that SK1 but not SK2 is activated in response to TNF-α and IL-1ß 
[Billich et al., 2005]. This is not surprising since SK1 has been implicated in the stimulation 
of cell growth and inflammatory responses, promotion of cell migration and inhibition of 
apoptosis. By contrast, SK2 has been involved in the inhibition of cell growth and stimulation 
of apoptosis [Le Stunff et al., 2004]. 
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The question arises on how SK1/and or its reaction product S1P might induce cytokine 
production. Xia et al. using HEK 293T cells as a model system showed that SK1 directly 
interacts with TNF receptor-associated factor 2 (TRAF2), resulting in activation of the 
enzyme, which in turn is required for TRAF2-mediated activation of NF-kB [Xia et al., 2002]. 
Moreover, the dependence of proinflammatory mediator production on SK1 might be 
explained by interaction of S1P generated intracellularly with a yet unknown intracellular 
receptor or with extracellular receptors following secretion of S1P.   
4.2.4. Ceramide-1-phosphate is a potent and specific inducer of arachidonic 
acid release and PGE2 formation in RISM cells 
 
The finding that surgical manipulation induces an increase in the content of C1P in intestinal 
muscularis, determined us to investigate its possible implication in inflammatory responses in 
primary cultured RISM cells. We found that unlike S1P, C1P had no effect on COX-2 protein 
expression but like S1P also triggered PGE2 production. Therefore, we assumed that C1P acts 
on the initial rate-limiting step involved in PGE2 synthesis, namely PLA2 that catalyses the 
release of arachidonic acid from phospholipids. Our data indicate that C1P is an activator of 
PLA2 by inducing a time-dependent increase in arachidonic acid release. In addition, 
treatment of RISM cells with related lipids did not mimic C1P effects on arachidonic acid 
release, thus supporting the specificity of C1P in this regard [Dragusin et al., 2006]. Our 
findings are consistent with the ones from another study in which treatment of A549 cells 
with C1P alone stimulated arachidonic acid release and PGE2 production [Pettus et al., 
2003b]. The role of sphingolipids in cPLA2 regulation has come from an unexpected source. It 
is known that many types of venom induce acute inflammation by the activity of soluble 
venom PLA2. By contrast, it was reported that unlike SMase C that hydrolyses SM to 
ceramide, SMase D from Loxosceles recluses venom generates C1P [Merchant et al., 1998]. 
This finding led to the assumption that many of the actions attributed to ceramide might be 
explained by the action of C1P. It was reported that treatment of cells with SMase D elicited 
arachidonic acid release, whereas SMase C, which generates ceramide had no effect. 
Moreover, IL-1ß and calcium ionophore A23187 produced an increase in CK activity and 
elevated C1P levels. More important, RNAi targeted against CK, inhibited arachidonic acid 
release and PGE2 synthesis in response to IL-1ß and A23187 implicating CK as a mediator of 
cPLA2 activation [Pettus et al., 2003a]. Furthermore, it was demonstrated that C1P enhanced 
cPLA2 association with the membrane and was able to induce translocation of cPLA2 to the 
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Golgi and perinuclear regions. Collectively, these results implicate CK/C1P in activation of 
cPLA2 upstream of COX-2 induction.  
4.2.5. Mechanical stress activates sphingolipid kinases in RISM cells 
 
To find out whether mechanical stress assumed to be causative for the inflammatory processes 
of intestinal muscularis is correlated with increased levels of S1P and C1P, muscle cells were 
subjected to mechanical stretch to mimic the insult that has been reported to induce 
postoperative ileus. We found that mechanical stress indeed activates SK, and simultaneously 
an enhancement of C1P content was observed. The latter observation could be explained by 
activation of CK during mechanical stress, its substrate, ceramide being highly abundant in 
RISM cells. These results together with the ones obtained after manipulation of small 
intestine suggest that activation of SK and CK occur quite early after manipulation (between 4 
h - 6 h). Moreover, in RISM cells, mechanical stretch induces release of inflammatory 
mediators suggesting that together with other cells that reside within the muscularis layer they 
participate in inflammatory responses during postoperative ileus. 
In conclusion, we could show for the first time that S1P and C1P are potential 
proinflammatory mediators using manipulated rat small intestine and RISM cells. It has been 
suggested very recently that C1P and S1P may act in concert to regulate PGE2 production 
[Pettus et al., 2005]. This suggestion is strongly supported by the following findings of the 
present study: i) the similarity of the time course concerning the increased levels of both 
sphingolipid metabolites in the muscle layer after intestinal manipulation, ii) stimulation of 
COX-2 expression and arachidonic acid release by S1P and C1P, respectively and iii) the 
early but transient versus a continuously increase of PGE2 formation induced by S1P and 
C1P, respectively (Fig. 25). The latter finding also supports the hypothesis that S1P primes 
the system for PGE2 synthesis by inducing COX-2 [Chalfant and Spiegel, 2005]. The fact that 
both stimulate synthesis of PGE2 and that S1P induces IL-6 release makes them interesting 
targets for development of novel anti-inflammatory drugs. 
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Fig. 25 Scheme of proposed mechanism of sphingolipid involvement in inflammatory responses generated 
by surgical manipulation of the bowel.  
4.3. Endotoxemia increases the contents of sphingosine-1-phosphate and 
ceramide-1-phosphate in the intestinal muscularis  
 
The intestine has been hypothesized to play an important role in both septic shock and 
multiple-organ failure as an endogenous source of not only bacterial products but also 
proinflammatory cytokines, which circulate systemically leading to functional detriment of 
distant organs [Mainous et al., 1995; Grotz et al., 1999]. However the intestine itself is a 
major target of self-derived bacterial products and cytokines. It was shown that intraperitoneal 
injection of endotoxin (LPS) elicits an inflammatory response within the intestinal muscularis 
by activation of resident macrophages. LPS-activated macrophages were able to secrete a 
plethora of cytokines and kinetic active substances (NO, PGE2) resulting in recruitment of 
numerous leukocytes [Sweet and Hume, 1996]. This inflammatory response in the intestinal 
muscularis was found to suppress smooth muscle contractility, LPS being known as a 
causative factor of sepsis-induced ileus [Eskandari et al., 1997; Eskandari et al., 1999]. In 
order to study the possible involvement of sphingolipids in LPS-induced inflammatory 
reactions, we used a well-established sepsis model that implies bolus intraperitoneal 
administration of LPS. Lipid content was determined in both, mucosa and muscularis at 
different time intervals after LPS administration. In the mucosa layer no significant changes 
in any of the sphingolipid analysed could be detected. By contrast, in tunica muscularis we 
found an increase in the content of S1P and C1P already after 3 h, the maximum being 
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reached at 12 h post LPS injection. It has been previously shown that LPS initiates an 
inflammatory response that consists of an activation of a normally quiescent network of 
resident intestinal muscularis macrophages. Moreover, LPS induced recruitment of 
polymorphonucleated leucocytes within intestinal muscularis maximum being reached at 12 h 
after LPS administration [Buchholz, 2005]. Recruited cells degranulate and release 
inflammatory mediators including reactive oxygen intermediates, nitric oxide, prostaglandins 
and histamine, which may suppress smooth muscle contractile activity [Eskandari et al., 
1997]. It was found that S1P acts as an effective regulator of migration of freshly isolated 
human neutrophils across endothelial cells [Kawa et al., 1997; MacKinnon et al., 2002]. 
Therefore, one might suggest the involvement of S1P and C1P in recruitment of leucocytes in 
the intestinal muscularis explaining their increased levels 12 h after LPS injection. Leucocyte 
infiltration in rat intestinal muscularis was also reported at 24 h after gentle surgical intestinal 
manipulation. Leucocyte extravasation occurs as a result of a significant up-regulation of 
adhesion molecules within the vasculature of rat intestinal muscularis [Kalff et al., 2003]. 
Similar results regarding activation of resident intestinal muscularis macrophages, induction 
and release of inflammatory cytokines (IL-6, IL-1ß, TNF-α) and kinetic active mediators 
(NO, PGE2) as well as recruitment of leukocytes could be shown in human small bowel 
specimens harvested during abdominal procedures [Kalff et al., 2003].  
4.4. Sphingolipid kinases mediate LPS-induced inflammatory responses 
 
Our results obtained with intestinal tissue after LPS injections indicate that S1P and or C1P 
might mediate inflammatory responses. Even though it was suggested that resident muscularis 
macrophages release various inflammatory cytokines after LPS injection, we cannot exclude 
that smooth muscle cells also participate in the inflammatory cascade. In the present study we 
found that RISM cells have the capacity to produce IL-6 in response to LPS. Moreover, this 
process is mediated by S1P formation since IL-6 secretion was suppressed by DMS, a specific 
SK inhibitor. In addition, the enzymatic activity of SK and increased after treatment of RISM 
cells with LPS suggesting that SK mediate LPS-induced IL-6 production. We have also 
observed an increase formation of C1P indicating the possible activation of CK. Taken 
together our data suggest that not only resident muscularis macrophages but also RISM cells 
might participate in endotoxemia involving sphingolipid phosphorylation. A recent study 
showed that LPS stimulates SK activity in a murine macrophage cell line and that SK is 
involved in LPS activation of NF-kB [Wu et al., 2004]. The transcription factor NF-kB is 
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involved in the expression of many inflammatory mediators [Karin and Ben-Neriah, 2000]. It 
would be interesting to investigate whether LPS also activates SK in muscularis macrophages.  
Our findings after LPS administration fit together with the ones obtained upon intestinal 
manipulation and mechanical stretch of RISM cells indicating the involvement of S1P and 
C1P in inflammatory responses derived thereof. This is not surprising since both sepsis- and 
postoperative-induced ileus share similar mechanisms. 
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